Michael A. Pfaller

Michael A. Pfaller's AcademicInfluence.com Rankings

Michael A. Pfaller

Biology

#1837

World Rank

#2981

Historical Rank

Microbiology

#34

World Rank

#49

Historical Rank

biology Degrees

Download Badge

Biology

Michael A. Pfaller's Degrees

PhD Microbiology University of Iowa

Why Is Michael A. Pfaller Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Michael A. Pfaller's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Manual of clinical microbiology (1975) (11738)
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem (2007) (3773)
Nosocomial bloodstream infections in United States hospitals: a three-year analysis. (1999) (1449)
Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. (2001) (1432)
Attributable mortality of nosocomial candidemia, revisited. (2003) (1130)
Hospital-acquired candidemia. The attributable mortality and excess length of stay. (1988) (907)
Resistance of Candida species to fluconazole (1995) (904)
Epidemiology of Invasive Mycoses in North America (2010) (865)
Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Labora (1997) (840)
Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. (2012) (822)
Rare and Emerging Opportunistic Fungal Pathogens: Concern for Resistance beyond Candida albicans and Aspergillus fumigatus (2004) (708)
Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-Year Analysis of Susceptibilities of Candida Species to Fluconazole and Voriconazole as Determined by CLSI Standardized Disk Diffusion (2010) (666)
Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. (2001) (659)
A Controlled Clinical Trial of E5 Murine Monoclonal IgM Antibody to Endotoxin in the Treatment of Gram-Negative Sepsis (1991) (656)
Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. (2013) (627)
Intranasal mupirocin to prevent postoperative Staphylococcus aureus infections. (2002) (621)
Risk factors for hospital-acquired candidemia. A matched case-control study. (1989) (572)
Bacterial Pathogens Isolated from Patients with Bloodstream Infection: Frequencies of Occurrence and Antimicrobial Susceptibility Patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997) (1998) (556)
Risk factors for candidemia in Neonatal Intensive Care Unit patients (2000) (549)
International Surveillance of Bloodstream Infections Due toCandida Species: Frequency of Occurrence and In Vitro Susceptibilities to Fluconazole, Ravuconazole, and Voriconazole of Isolates Collected from 1997 through 1999 in the SENTRY Antimicrobial Surveillance Program (2001) (539)
Nosocomial candidiasis: emerging species, reservoirs, and modes of transmission. (1996) (520)
Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection. (1995) (505)
The epidemiology of candidemia in two United States cities: results of a population-based active surveillance. (1999) (471)
Invasive Fungal Pathogens: Current Epidemiological Trends (2006) (460)
Antifungal Susceptibilities of Candida Species Causing Vulvovaginitis and Epidemiology of Recurrent Cases (2005) (439)
Antifungal Susceptibility Testing: Practical Aspects and Current Challenges (2001) (438)
Multicenter evaluation of four methods of yeast inoculum preparation (1988) (437)
National epidemiology of mycoses survey (NEMIS): variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units. (1999) (432)
National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. SCOPE Participant Group. Surveillance and Control of Pathogens of Epidemiologic. (1998) (425)
Progress in Antifungal Susceptibility Testing of Candida spp. by Use of Clinical and Laboratory Standards Institute Broth Microdilution Methods, 2010 to 2012 (2012) (422)
International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections. (1997) (422)
Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. (2004) (421)
Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY antimicrobial surveillance program. (1998) (420)
Epidemiology of Candidemia: 3-Year Results from the Emerging Infections and the Epidemiology of Iowa Organisms Study (2002) (395)
In Vitro Susceptibility of Invasive Isolates of Candida spp. to Anidulafungin, Caspofungin, and Micafungin: Six Years of Global Surveillance (2007) (393)
Bloodstream Infections Due to Candida Species: SENTRY Antimicrobial Surveillance Program in North America and Latin America, 1997-1998 (2000) (392)
Antifungal Activities of Posaconazole, Ravuconazole, and Voriconazole Compared to Those of Itraconazole and Amphotericin B against 239 Clinical Isolates of Aspergillus spp. and Other Filamentous Fungi: Report from SENTRY Antimicrobial Surveillance Program, 2000 (2002) (385)
Comparative Efficacy of Alternative Hand-Washing Agents in Reducing Nosocomial Infections in Intensive Care Units (1992) (380)
Candida, Cryptococcus, and other yeasts of medical importance. (2006) (377)
Laboratory, clinical, and epidemiological aspects of coagulase-negative staphylococci (1988) (366)
Activities of Caspofungin, Itraconazole, Posaconazole, Ravuconazole, Voriconazole, and Amphotericin B against 448 Recent Clinical Isolates of Filamentous Fungi (2003) (358)
A swimming-associated outbreak of hemorrhagic colitis caused by Escherichia coli O157:H7 and Shigella sonnei. (1994) (350)
Has antifungal susceptibility testing come of age? (2002) (344)
Epidemiology and outcomes of candidemia in 3648 patients: data from the Prospective Antifungal Therapy (PATH Alliance®) registry, 2004-2008. (2012) (342)
Epidemiology and Outcomes of Invasive Candidiasis Due to Non-albicans Species of Candida in 2,496 Patients: Data from the Prospective Antifungal Therapy (PATH) Registry 2004–2008 (2014) (336)
Twenty Years of the SENTRY Antifungal Surveillance Program: Results for Candida Species From 1997–2016 (2019) (333)
Trends in Antifungal Susceptibility of Candida spp. Isolated from Pediatric and Adult Patients with Bloodstream Infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000 (2002) (331)
Risk factors for Candida species colonization of neonatal intensive care unit patients. (2001) (329)
Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: 10.5-Year Analysis of Susceptibilities of Noncandidal Yeast Species to Fluconazole and Voriconazole Determined by CLSI Standardized Disk Diffusion Testing (2007) (328)
Elimination of coincident Staphylococcus aureus nasal and hand carriage with intranasal application of mupirocin calcium ointment. (1991) (328)
Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. (2011) (327)
Survey of bloodstream infections due to gram-negative bacilli: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, and Latin America for the SENTRY Antimicrobial Surveillance Program, 1997. (1999) (327)
National surveillance of nosocomial blood stream infection due to Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. (1998) (323)
Coagulase-negative staphylococcal bacteremia. Mortality and hospital stay. (1989) (305)
International Surveillance of Bloodstream Infections Due to Candida Species: Frequency of Occurrence and Antifungal Susceptibilities of Isolates Collected in 1997 in the United States, Canada, and South America for the SENTRY Program (1998) (303)
Interpretive Breakpoints for Fluconazole and Candida Revisited: a Blueprint for the Future of Antifungal Susceptibility Testing (2006) (300)
The changing epidemiology of healthcare-associated candidemia over three decades. (2012) (297)
Reduced intravascular catheter infection by antibiotic bonding. A prospective, randomized, controlled trial. (1991) (297)
Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods. (2010) (296)
Methicillin-Resistant Staphylococcus aureus Outbreak in a Veterinary Teaching Hospital: Potential Human-to-Animal Transmission (1999) (296)
Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2005: an 8.5-Year Analysis of Susceptibilities of Candida Species and Other Yeast Species to Fluconazole and Voriconazole Determined by CLSI Standardized Disk Diffusion Testing (2007) (294)
Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. NIAID Mycoses Study Group and the Candidemia Study Group (1995) (292)
Role of Sentinel Surveillance of Candidemia: Trends in Species Distribution and Antifungal Susceptibility (2002) (285)
Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. (2004) (282)
Animal and Human Multidrug-Resistant, Cephalosporin-ResistantSalmonella Isolates Expressing a Plasmid-Mediated CMY-2 AmpC β-Lactamase (2000) (281)
International surveillance of blood stream infections due to Candida species in the European SENTRY Program: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. SENTRY Participant Group (Europe). (1999) (277)
Influence of Test Conditions on Antifungal Time-Kill Curve Results: Proposal for Standardized Methods (1998) (275)
Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: documentation by in vitro susceptibility testing and DNA subtype analysis. (1994) (272)
Correlation of MIC with Outcome for Candida Species Tested against Voriconazole: Analysis and Proposal for Interpretive Breakpoints (2006) (272)
Determination of Fungicidal Activities against Yeasts and Molds: Lessons Learned from Bactericidal Testing and the Need for Standardization (2004) (257)
Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests (1992) (254)
Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi (1995) (250)
In Vitro Activities of Ravuconazole and Voriconazole Compared with Those of Four Approved Systemic Antifungal Agents against 6,970 Clinical Isolates of Candida spp (2002) (250)
Correlation of MIC with Outcome for Candida Species Tested against Caspofungin, Anidulafungin, and Micafungin: Analysis and Proposal for Interpretive MIC Breakpoints (2008) (250)
In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program. (2004) (247)
Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008-2009). (2011) (246)
Survey of blood stream infections attributable to gram-positive cocci: frequency of occurrence and antimicrobial susceptibility of isolates collected in 1997 in the United States, Canada, and Latin America from the SENTRY Antimicrobial Surveillance Program. SENTRY Participants Group. (1999) (244)
Detection of circulating candida enolase by immunoassay in patients with cancer and invasive candidiasis. (1991) (243)
Candida Bloodstream Infections: Comparison of Species Distributions and Antifungal Resistance Patterns in Community-Onset and Nosocomial Isolates in the SENTRY Antimicrobial Surveillance Program, 2008-2009 (2010) (239)
In Candida albicans, white-opaque switchers are homozygous for mating type. (2002) (238)
Antifungal susceptibility testing (1993) (234)
Results from the ARTEMIS DISK Global AntifungalSurveillance Study: a 6.5-Year Analysis of Susceptibilitiesof Candida and Other Yeast Species to Fluconazole andVoriconazole by Standardized Disk Diffusion Testing (2005) (234)
Usefulness of a test for slime production as a marker for clinically significant infections with coagulase-negative staphylococci. (1986) (232)
Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi (1997) (232)
In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. (1998) (232)
Trends in species distribution and susceptibility to fluconazole among blood stream isolates of Candida species in the United States. (1999) (230)
Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans (1997) (230)
Candida krusei, a Multidrug-Resistant Opportunistic Fungal Pathogen: Geographic and Temporal Trends from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005 (2007) (230)
Removal of nosocomial pathogens from the contaminated glove. Implications for glove reuse and handwashing. (1988) (229)
Echinocandin and Triazole Antifungal Susceptibility Profiles for Clinical Opportunistic Yeast and Mold Isolates Collected from 2010 to 2011: Application of New CLSI Clinical Breakpoints and Epidemiological Cutoff Values for Characterization of Geographic and Temporal Trends of Antifungal Resistance (2013) (229)
Epidemiology and frequency of resistance among pathogens causing urinary tract infections in 1,510 hospitalized patients: a report from the SENTRY Antimicrobial Surveillance Program (North America). (2001) (227)
Quality Control Limits for Broth Microdilution Susceptibility Tests of Ten Antifungal Agents (2000) (225)
Azole Resistance in Aspergillus fumigatus Isolates from the ARTEMIS Global Surveillance Study Is Primarily Due to the TR/L98H Mutation in the cyp51A Gene (2011) (224)
Investigation of the sequence of colonization and candidemia in nonneutropenic patients (1994) (221)
Wild-Type MIC Distributions and Epidemiological Cutoff Values for the Triazoles and Six Aspergillus spp. for the CLSI Broth Microdilution Method (M38-A2 Document) (2010) (220)
Staphylococcus, Micrococcus, and Other Catalase-Positive Cocci (2020) (220)
Nosocomial bloodstream infections caused by Acinetobacter species in United States hospitals: clinical features, molecular epidemiology, and antimicrobial susceptibility. (2000) (219)
Antimicrobial resistance trends and outbreak frequency in United States hospitals. (2004) (217)
Activity and spectrum of 22 antimicrobial agents tested against urinary tract infection pathogens in hospitalized patients in Latin America: report from the second year of the SENTRY antimicrobial surveillance program (1998). (2000) (213)
Global Trends in the Antifungal Susceptibility of Cryptococcus neoformans (1990 to 2004) (2005) (211)
Characterization of the sequence of colonization and nosocomial candidemia using DNA fingerprinting and a DNA probe (1990) (210)
Geographic Variations in Species Distribution and Echinocandin and Azole Antifungal Resistance Rates among Candida Bloodstream Infection Isolates: Report from the SENTRY Antimicrobial Surveillance Program (2008 to 2009) (2010) (210)
The Microbiology of Bloodstream Infection: 20-Year Trends from the SENTRY Antimicrobial Surveillance Program (2019) (210)
Manual of Clinical Microbiology, 11th Edition (2015) (208)
The PATH (Prospective Antifungal Therapy) Alliance® registry and invasive fungal infections: update 2012. (2012) (207)
Activities of Fluconazole and Voriconazole against 1,586 Recent Clinical Isolates of Candida Species Determined by Broth Microdilution, Disk Diffusion, and Etest Methods: Report from The ARTEMIS Global Antifungal Susceptibility Program, 2001 (2003) (206)
Methicillin-resistant Staphylococcus aureus: implications for the 1990s and effective control measures. (1991) (204)
Cryptococcus neoformans-Cryptococcus gattii Species Complex: an International Study of Wild-Type Susceptibility Endpoint Distributions and Epidemiological Cutoff Values for Fluconazole, Itraconazole, Posaconazole, and Voriconazole (2012) (200)
In Vitro Susceptibilities of Candida spp. to Caspofungin: Four Years of Global Surveillance (2006) (200)
Interlaboratory Variability of Caspofungin MICs for Candida spp. Using CLSI and EUCAST Methods: Should the Clinical Laboratory Be Testing This Agent? (2013) (195)
Collaborative investigation of variables in susceptibility testing of yeasts (1990) (194)
Comparison of Etest, chequerboard dilution and time-kill studies for the detection of synergy or antagonism between antifungal agents tested against Candida species. (2002) (193)
Variations in fluconazole susceptibility and electrophoretic karyotype among oral isolates of Candida albicans from patients with AIDS and oral candidiasis (1994) (193)
Geographic Distribution and Antifungal Susceptibility of the Newly Described Species Candida orthopsilosis and Candida metapsilosis in Comparison to the Closely Related Species Candida parapsilosis (2008) (193)
Geographic Variation in the Susceptibilities of Invasive Isolates of Candida glabrata to Seven Systemically Active Antifungal Agents: a Global Assessment from the ARTEMIS Antifungal Surveillance Program Conducted in 2001 and 2002 (2004) (191)
Elimination of Staphylococcus aureus nasal carriage in health care workers: analysis of six clinical trials with calcium mupirocin ointment. The Mupirocin Collaborative Study Group. (1993) (189)
Multicenter evaluation of a broth macrodilution antifungal susceptibility test for yeasts (1993) (189)
In Vivo Comparison of the Pharmacodynamic Targets for Echinocandin Drugs against Candida Species (2010) (186)
Overview of the Epidemiological Profileand Laboratory Detection of Extended-Spectrum β-Lactamases (2006) (186)
In Vitro Activities of Anidulafungin against More than 2,500 Clinical Isolates of Candida spp., Including 315 Isolates Resistant to Fluconazole (2005) (183)
Candida albicans and Candida glabrata Clinical Isolates Exhibiting Reduced Echinocandin Susceptibility (2006) (182)
Interlaboratory Comparison of Results of Susceptibility Testing with Caspofungin against Candida and Aspergillus Species (2004) (177)
Haemophilus influenzae and Moraxella catarrhalis from Patients with Community-Acquired Respiratory Tract Infections: Antimicrobial Susceptibility Patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997) (1999) (175)
In Vitro Activities of Voriconazole, Posaconazole, and Four Licensed Systemic Antifungal Agents against Candida Species Infrequently Isolated from Blood (2003) (175)
Pathogen frequency and resistance patterns in Brazilian hospitals: summary of results from three years of the SENTRY Antimicrobial Surveillance Program. (2001) (173)
Prevalence of extended spectrum beta-lactamase (ESBL)-producing clinical isolates in the Asia-Pacific region and South Africa: regional results from SENTRY Antimicrobial Surveillance Program (1998-99). (2002) (171)
Variation in Candida spp. distribution and antifungal resistance rates among bloodstream infection isolates by patient age: report from the SENTRY Antimicrobial Surveillance Program (2008-2009). (2010) (171)
Candida guilliermondii, an Opportunistic Fungal Pathogen with Decreased Susceptibility to Fluconazole: Geographic and Temporal Trends from the ARTEMIS DISK Antifungal Surveillance Program (2006) (170)
Postantifungal Effects of Echinocandin, Azole, and Polyene Antifungal Agents against Candida albicans andCryptococcus neoformans (2000) (168)
Epidemiology and control of fungal infections. (1994) (168)
In Vitro Activities of Caspofungin Compared with Those of Fluconazole and Itraconazole against 3,959 Clinical Isolates of Candida spp., Including 157 Fluconazole-Resistant Isolates (2003) (164)
Vertical and horizontal transmission of unique Candida species to premature newborns. (1996) (162)
Characteristics of pathogens causing urinary tract infections in hospitals in North America: results from the SENTRY Antimicrobial Surveillance Program, 1997. (1999) (162)
Vancomycin resistance in Staphylococcus haemolyticus causing colonization and bloodstream infection (1990) (162)
Evaluation of a novel colorimetric broth microdilution method for antifungal susceptibility testing of yeast isolates (1994) (160)
Nosocomial enterococcal blood stream infections in the SCOPE Program: antimicrobial resistance, species occurrence, molecular testing results, and laboratory testing accuracy. SCOPE Hospital Study Group. (1997) (159)
Contemporary Tools for the Diagnosis and Management of Invasive Mycoses (2006) (157)
Evaluation of Possible Correlations between Antifungal Susceptibilities of Filamentous Fungi In Vitro and Antifungal Treatment Outcomes in Animal Infection Models (1998) (155)
The positive predictive value of isolating coagulase-negative staphylococci from blood cultures. (1996) (155)
Nosocomial pneumonia in adult patients undergoing bone marrow transplantation: a 9-year study. (1991) (152)
Comparative efficacy of alternative hand-washing agents in reducing nosocomial infections in intensive care units. (1992) (151)
Bacterial resistance: a worldwide problem. (1998) (151)
Bacterial pathogens isolated from patients with skin and soft tissue infections: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997). SENTRY Study Group (North America). (1999) (148)
Minimizing the Workup of Blood Culture Contaminants: Implementation and Evaluation of a Laboratory-Based Algorithm (2002) (147)
Trends in Antifungal Use and Epidemiology of Nosocomial Yeast Infections in a University Hospital (1999) (146)
International and Multicenter Comparison of EUCAST and CLSI M27-A2 Broth Microdilution Methods for Testing Susceptibilities of Candida spp. to Fluconazole, Itraconazole, Posaconazole, and Voriconazole (2005) (144)
Effect of a Second-Generation Venous Catheter Impregnated with Chlorhexidine and Silver Sulfadiazine on Central CatheterRelated Infections (2005) (144)
Multicenter Comparison of the VITEK 2 Antifungal Susceptibility Test with the CLSI Broth Microdilution Reference Method for Testing Amphotericin B, Flucytosine, and Voriconazole against Candida spp (2007) (144)
National epidemiology of mycoses survey: a multicenter study of strain variation and antifungal susceptibility among isolates of Candida species. (1998) (144)
In Vitro Susceptibilities of Candida dubliniensisIsolates Tested against the New Triazole and Echinocandin Antifungal Agents (1999) (144)
Wild-Type MIC Distributions and Epidemiological Cutoff Values for Amphotericin B and Aspergillus spp. for the CLSI Broth Microdilution Method (M38-A2 Document) (2011) (143)
In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods. (1999) (143)
Staphylococcus aureus and coagulase-negative staphylococci from blood stream infections: frequency of occurrence, antimicrobial susceptibility, and molecular (mecA) characterization of oxacillin resistance in the SCOPE program. (1998) (139)
In Vitro Activities of Posaconazole (Sch 56592) Compared with Those of Itraconazole and Fluconazole against 3,685 Clinical Isolates of Candida spp. andCryptococcus neoformans (2001) (139)
Lysis of Plasmodium falciparum by ferriprotoporphyrin IX and a chloroquine-ferriprotoporphyrin IX complex (1982) (137)
Wild-Type MIC Distributions and Epidemiological Cutoff Values for Amphotericin B, Flucytosine, and Itraconazole and Candida spp. as Determined by CLSI Broth Microdilution (2012) (135)
Emergence of Fluconazole Resistance in a Candida parapsilosis Strain That Caused Infections in a Neonatal Intensive Care Unit (2005) (133)
Trends in Antifungal Drug Susceptibility of Cryptococcus neoformans Isolates in the United States: 1992 to 1994 and 1996 to 1998 (2001) (133)
Group B streptococci causing neonatal bloodstream infection: antimicrobial susceptibility and serotyping results from SENTRY centers in the Western Hemisphere. (2000) (133)
A Prospective Study of Outcomes, Healthcare Resource Utilization, and Costs Associated With Postoperative Nosocomial Infections (2006) (132)
Cost of nosocomial infection: relative contributions of laboratory, antibiotic, and per diem costs in serious Staphylococcus aureus infections. (1988) (132)
Variation in Susceptibility of Bloodstream Isolates of Candida glabrata to Fluconazole According to Patient Age and Geographic Location in the United States in 2001 to 2007 (2009) (132)
Wild-Type MIC Distribution and Epidemiological Cutoff Values for Aspergillus fumigatus and Three Triazoles as Determined by the Clinical and Laboratory Standards Institute Broth Microdilution Methods (2009) (132)
In Vivo Pharmacodynamic Characterization of Anidulafungin in a Neutropenic Murine Candidiasis Model (2007) (131)
In Vitro Susceptibilities of CandidaBloodstream Isolates to the New Triazole Antifungal Agents BMS-207147, Sch 56592, and Voriconazole (1998) (131)
Quality control guidelines for National Committee for Clinical Laboratory Standards recommended broth macrodilution testing of amphotericin B, fluconazole, and flucytosine (1995) (130)
Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Etest Methods with the CLSI Broth Microdilution Method for Echinocandin Susceptibility Testing of Candida Species (2010) (127)
Antimicrobial susceptibility patterns for pathogens isolated from patients in Latin American medical centers with a diagnosis of pneumonia: analysis of results from the SENTRY Antimicrobial Surveillance Program (1997). SENTRY Latin America Study Group. (1998) (126)
Stable azole drug resistance associated with a substrain of Candida albicans from an HIV-infected patient. (1997) (126)
Multicenter Comparison of the Sensititre YeastOne Colorimetric Antifungal Panel with the National Committee for Clinical Laboratory Standards M27-A Reference Method for Testing Clinical Isolates of Common and Emerging Candidaspp., Cryptococcus spp., and Other Yeasts and Yeast-Like Organisms (1999) (126)
In Vitro Survey of Triazole Cross-Resistance among More than 700 Clinical Isolates of Aspergillus Species (2008) (125)
Manual of Clinical Microbiology, 8th Edition . (2004) (125)
Antifungal susceptibility testing: technical advances and potential clinical applications. (1997) (125)
In Vivo Pharmacodynamic Target Investigation for Micafungin against Candida albicans and C. glabrata in a Neutropenic Murine Candidiasis Model (2008) (125)
Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria. (2011) (125)
Trends in antimicrobial susceptibility of bacterial pathogens isolated from patients with bloodstream infections in the USA, Canada and Latin America. SENTRY Participants Group. (2000) (124)
Cryptococcus neoformans-Cryptococcus gattii Species Complex: an International Study of Wild-Type Susceptibility Endpoint Distributions and Epidemiological Cutoff Values for Amphotericin B and Flucytosine (2012) (123)
Epidemiologic trends in nosocomial and community-acquired infections due to antibiotic-resistant gram-positive bacteria: the role of streptogramins and other newer compounds. (1999) (122)
Multicenter Evaluation of a New Disk Agar Diffusion Method for Susceptibility Testing of Filamentous Fungi with Voriconazole, Posaconazole, Itraconazole, Amphotericin B, and Caspofungin (2007) (122)
Clade-Specific Flucytosine Resistance Is Due to a Single Nucleotide Change in the FUR1 Gene of Candida albicans (2004) (122)
Long-term efficacy of intranasal mupirocin ointment. A prospective cohort study of Staphylococcus aureus carriage. (1994) (121)
In Vitro Activity of Seven Systemically Active Antifungal Agents against a Large Global Collection of Rare Candida Species as Determined by CLSI Broth Microdilution Methods (2009) (121)
Effect of a second-generation venous catheter impregnated with chlorhexidine and silver sulfadiazine on central catheter-related infections: a randomized, controlled trial. (2005) (120)
Nosocomial Candidiasis: Antifungal Stewardship and the Importance of Rapid Diagnosis. (2015) (120)
Overview of the epidemiological profile and laboratory detection of extended-spectrum beta-lactamases. (2006) (120)
Low Prevalence of fks1 Hot Spot 1 Mutations in a Worldwide Collection of Candida Strains (2010) (119)
In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa. (1999) (119)
T2MR and T2Candida: novel technology for the rapid diagnosis of candidemia and invasive candidiasis. (2016) (118)
Control of Methicillin-Resistant Staphylococcus Aureus in a Hospital and an Intensive Care Unit (1995) (118)
Caspofungin Activity against Clinical Isolates of Fluconazole-Resistant Candida (2003) (117)
Nosocomial pneumonia in patients having bone marrow transplant attributable mortality and risk factors (1992) (116)
Aspergillus, Fusarium, and other opportunistic moniliaceous fungi. (2006) (116)
In Vitro Activities of 5-Fluorocytosine against 8,803 Clinical Isolates of Candida spp.: Global Assessment of Primary Resistance Using National Committee for Clinical Laboratory Standards Susceptibility Testing Methods (2002) (116)
Geographic and Temporal Trends in Isolation and Antifungal Susceptibility of Candida parapsilosis: a Global Assessment from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005 (2008) (116)
Interlaboratory evaluation of Etest method for testing antifungal susceptibilities of pathogenic yeasts to five antifungal agents by using Casitone agar and solidified RPMI 1640 medium with 2% glucose (1996) (115)
Emerging elevated mupirocin resistance rates among staphylococcal isolates in the SENTRY Antimicrobial Surveillance Program (2000): correlations of results from disk diffusion, Etest and reference dilution methods. (2002) (115)
Activity of MGCD290, a Hos2 Histone Deacetylase Inhibitor, in Combination with Azole Antifungals against Opportunistic Fungal Pathogens (2009) (115)
Echinocandin and triazole antifungal susceptibility profiles for Candida spp., Cryptococcus neoformans, and Aspergillus fumigatus: application of new CLSI clinical breakpoints and epidemiologic cutoff values to characterize resistance in the SENTRY Antimicrobial Surveillance Program (2009). (2011) (114)
Comparative evaluation of an automated ribotyping system versus pulsed-field gel electrophoresis for epidemiological typing of clinical isolates of Escherichia coli and Pseudomonas aeruginosa from patients with recurrent gram-negative bacteremia. (1996) (113)
Postoperative pneumonia: a prospective study of risk factors and morbidity. (1993) (111)
Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp. (1998) (110)
Age-related trends in pathogen frequency and antimicrobial susceptibility of bloodstream isolates in North America: SENTRY Antimicrobial Surveillance Program, 1997-2000. (2002) (110)
Inducible amp C beta-lactamase producing gram-negative bacilli from blood stream infections: frequency, antimicrobial susceptibility, and molecular epidemiology in a national surveillance program (SCOPE). (1997) (110)
Plasma tumor necrosis factor levels in patients with presumed sepsis. Results in those treated with antilipid A antibody vs placebo. (1989) (109)
Precision and Accuracy of Fluconazole Susceptibility Testing by Broth Microdilution, Etest, and Disk Diffusion Methods (2002) (109)
Antimicrobial Activity and Spectrum Investigation of Eight Broad-Spectrum β-Lactam Drugs: A 1997 Surveillance Trial in 102 Medical Centers in the United States (1998) (108)
Comparison of broth macrodilution, broth microdilution, and E test antifungal susceptibility tests for fluconazole (1994) (107)
Activities of Available and Investigational Antifungal Agents against Rhodotorula Species (2005) (107)
Evaluation of the Etest Method for Determining Fluconazole Susceptibilities of 402 Clinical Yeast Isolates by Using Three Different Agar Media (1998) (106)
Twenty-Year Trends in Antimicrobial Susceptibilities Among Staphylococcus aureus From the SENTRY Antimicrobial Surveillance Program (2019) (106)
Comparison of visual and spectrophotometric methods of MIC endpoint determinations by using broth microdilution methods to test five antifungal agents, including the new triazole D0870 (1995) (105)
The molecular epidemiology of penicillin-resistant Streptococcus pneumoniae in the United States, 1994-2000. (2002) (105)
Antifungal susceptibility patterns of a global collection of fungal isolates: results of the SENTRY Antifungal Surveillance Program (2013). (2016) (104)
Intra- and Interlaboratory Study of a Method for Testing the Antifungal Susceptibilities of Dermatophytes (2004) (103)
Isavuconazole, micafungin, and 8 comparator antifungal agents' susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: temporal analysis of antifungal drug resistance using CLSI species-specific clinical breakpoints and proposed epidemiological cutoff values. (2015) (103)
Ca3 Fingerprinting of Candida albicans Bloodstream Isolates from the United States, Canada, South America, and Europe Reveals a European Clade (2002) (103)
Variation in Susceptibility of Bloodstream Isolates of Candida glabrata to Fluconazole According to Patient Age and Geographic Location (2003) (103)
In Vitro Susceptibility of Clinical Isolates of Aspergillus spp. to Anidulafungin, Caspofungin, and Micafungin: a Head-to-Head Comparison Using the CLSI M38-A2 Broth Microdilution Method (2009) (102)
Homozygosity at the Candida albicans MTL locus associated with azole resistance. (2002) (101)
In Vitro Susceptibility Testing of Filamentous Fungi: Comparison of Etest and Reference Microdilution Methods for Determining Itraconazole MICs (2000) (101)
International Evaluation of MIC Distributions and Epidemiological Cutoff Value (ECV) Definitions for Fusarium Species Identified by Molecular Methods for the CLSI Broth Microdilution Method (2015) (101)
Geographic variations in activity of broad-spectrum beta-lactams against Pseudomonas aeruginosa: summary of the worldwide SENTRY Antimicrobial Surveillance Program (1997-2000). (2002) (100)
Evaluation of Voriconazole Pharmacodynamics Using Time-Kill Methodology (2000) (100)
Antifungal activities of fluconazole, caspofungin (MK0991), and anidulafungin (LY 303366) alone and in combination against Candida spp. and Crytococcus neoformans via time-kill methods. (2002) (100)
Activities of Micafungin against 315 Invasive Clinical Isolates of Fluconazole-Resistant Candida spp (2006) (99)
Identification of Candida nivariensis and Candida bracarensis in a Large Global Collection of Candida glabrata Isolates: Comparison to the Literature (2009) (99)
Coagulase-negative staphylococcal bacteremia. Mortality and hospital stay (1990) (98)
In Vitro Activities of Voriconazole (UK-109,496) and Four Other Antifungal Agents against 394 Clinical Isolates ofCandida spp (1998) (98)
Antimicrobial activity and spectrum of rifaximin, a new topical rifamycin derivative. (1993) (98)
Outbreak of Candida rugosa candidemia: an emerging pathogen that may be refractory to amphotericin B therapy. (2003) (98)
Multilaboratory Study of Epidemiological Cutoff Values for Detection of Resistance in Eight Candida Species to Fluconazole, Posaconazole, and Voriconazole (2014) (97)
Candida rugosa, an Emerging Fungal Pathogen with Resistance to Azoles: Geographic and Temporal Trends from the ARTEMIS DISK Antifungal Surveillance Program (2006) (97)
Familial carriage of methicillin-resistant Staphylococcus aureus and subsequent infection in a premature neonate. (1995) (96)
Elevated Phenotypic Switching and Drug Resistance ofCandida albicans from Human Immunodeficiency Virus-Positive Individuals prior to First Thrush Episode (2000) (96)
Evaluation of Etest for determining in vitro susceptibility of yeast isolates to amphotericin B. (1998) (95)
Candida guilliermondii and Other Species of Candida Misidentified as Candida famata: Assessment by Vitek 2, DNA Sequencing Analysis, and Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry in Two Global Antifungal Surveillance Programs (2012) (94)
An outbreak of Candida parapsilosis prosthetic valve endocarditis. (1997) (94)
Global Surveillance of In Vitro Activity of Micafungin against Candida: a Comparison with Caspofungin by CLSI-Recommended Methods (2006) (94)
Outbreak of severe Pseudomonas aeruginosa infections caused by a contaminated drain in a whirlpool bathtub. (2000) (93)
In vitro activity of newer fluoroquinolones for respiratory tract infections and emerging patterns of antimicrobial resistance: data from the SENTRY antimicrobial surveillance program. (2000) (93)
Outbreak of Candida bloodstream infections associated with retrograde medication administration in a neonatal intensive care unit. (1992) (93)
Antifungal activity of a new triazole, voriconazole (UK-109,496), compared with three other antifungal agents tested against clinical isolates of filamentous fungi. (1998) (92)
Assessment of Antifungal Activities of Fluconazole and Amphotericin B Administered Alone and in Combination againstCandida albicans by Using a Dynamic In Vitro Mycotic Infection Model (1998) (92)
In vitro susceptibilities of rare Candida bloodstream isolates to ravuconazole and three comparative antifungal agents. (2004) (92)
Further Standardization of Broth Microdilution Methodology for In Vitro Susceptibility Testing of Caspofungin against Candida Species by Use of an International Collection of More than 3,000 Clinical Isolates (2004) (92)
Lodderomyces elongisporus Masquerading as Candida parapsilosis as a Cause of Bloodstream Infections (2007) (91)
Strain delineation and antifungal susceptibilities of epidemiologically related and unrelated isolates of Candida lusitaniae. (1994) (91)
Activity of a new triazole, Sch 56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiae (1997) (91)
Use of Fluconazole as a Surrogate Marker To Predict Susceptibility and Resistance to Voriconazole among 13,338 Clinical Isolates of Candida spp. Tested by Clinical and Laboratory Standards Institute-Recommended Broth Microdilution Methods (2006) (91)
Multicenter Comparison of the Sensititre YeastOne Colorimetric Antifungal Panel with the NCCLS M27-A2 Reference Method for Testing New Antifungal Agents against Clinical Isolates of Candida spp (2004) (89)
Optimal Susceptibility Testing Conditions for Detection of Azole Resistance in Aspergillus spp.: NCCLS Collaborative Evaluation (2001) (89)
Molecular approaches to diagnosing and managing infectious diseases: practicality and costs. (2001) (88)
Frequency of pathogen occurrence and antimicrobial susceptibility among community-acquired respiratory tract infections in the respiratory surveillance program study: microbiology from the medical office practice environment. (2001) (88)
Plasmodium falciparum: stage-specific lactate production in synchronized cultures. (1982) (88)
Comparison of Results of Voriconazole Disk Diffusion Testing for Candida Species with Results from a Central Reference Laboratory in the ARTEMIS Global Antifungal Surveillance Program (2005) (87)
Laboratory evaluation of leukocyte esterase and nitrite tests for the detection of bacteriuria (1985) (87)
Dispersal of Staphylococcus aureus Into the Air Associated With a Rhinovirus Infection (2005) (87)
Antibacterial activity of 41 antimicrobials tested against over 2773 bacterial isolates from hospitalized patients with pneumonia: I--results from the SENTRY Antimicrobial Surveillance Program (North America, 1998). (2001) (86)
Use of Epidemiological Cutoff Values To Examine 9-Year Trends in Susceptibility of Aspergillus Species to the Triazoles (2010) (86)
Quality Control and Reference Guidelines for CLSI Broth Microdilution Susceptibility Method (M38-A Document) for Amphotericin B, Itraconazole, Posaconazole, and Voriconazole (2005) (85)
An Outbreak of Serratia marcescens Infections Related to Contaminated Chlorhexidine (1998) (85)
Fatal Disseminated Trichoderma longibrachiatum Infection in an Adult Bone Marrow Transplant Patient: Species Identification and Review of the Literature (1999) (84)
Multicenter Study of Isavuconazole MIC Distributions and Epidemiological Cutoff Values for Aspergillus spp. for the CLSI M38-A2 Broth Microdilution Method (2013) (84)
In Vitro Susceptibilities of Clinical Isolates of Candida Species, Cryptococcus neoformans, and Aspergillus Species to Itraconazole: Global Survey of 9,359 Isolates Tested by Clinical and Laboratory Standards Institute Broth Microdilution Methods (2005) (83)
In vitro susceptibilities of clinical yeast isolates to a new echinocandin derivative, LY303366, and other antifungal agents (1997) (83)
Stenotrophomonas maltophilia: emergence of multidrug-resistant strains during therapy and in an in vitro pharmacodynamic chamber model (1996) (83)
Epidemiology of fungal infections: the promise of molecular typing. (1995) (83)
Preoperative Risk Factors for Nasal Carriage of Staphylococcus aureus (2004) (83)
Regional data analysis of Candida non‐albicans strains collected in United States medical sites over a 6‐year period, 2006–2011 (2014) (83)
Multicenter Comparison of the VITEK 2 Yeast Susceptibility Test with the CLSI Broth Microdilution Reference Method for Testing Fluconazole against Candida spp (2007) (82)
In Vitro Activities of Isavuconazole and Comparator Antifungal Agents Tested against a Global Collection of Opportunistic Yeasts and Molds (2013) (82)
Standardization of antifungal susceptibility testing. (1996) (82)
Geographic variation in the frequency of isolation and fluconazole and voriconazole susceptibilities of Candida glabrata: an assessment from the ARTEMIS DISK Global Antifungal Surveillance Program. (2010) (82)
Antimicrobial Activity of Ceftolozane-Tazobactam Tested Against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2013-2016) as Part of the Surveillance Program: Program to Assess Ceftolozane-Tazobactam Susceptibility. (2017) (81)
Characterization of biofilms formed by Candida parapsilosis, C. metapsilosis, and C. orthopsilosis. (2010) (81)
Legionnaires' disease associated with a hospital water system. A five-year progress report on continuous hyperchlorination. (1988) (80)
The clinical microbiology laboratory and infection control: emerging pathogens, antimicrobial resistance, and new technology. (1997) (80)
Activity of MK-3118, a new oral glucan synthase inhibitor, tested against Candida spp. by two international methods (CLSI and EUCAST). (2013) (80)
Monitoring Antifungal Resistance in a Global Collection of Invasive Yeasts and Molds: Application of CLSI Epidemiological Cutoff Values and Whole-Genome Sequencing Analysis for Detection of Azole Resistance in Candida albicans (2017) (79)
In Vitro Susceptibility Testing of Aspergillus spp.: Comparison of Etest and Reference Microdilution Methods for Determining Voriconazole and Itraconazole MICs (2003) (79)
Flavophospholipol use in animals: positive implications for antimicrobial resistance based on its microbiologic properties. (2006) (79)
Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, against Candida and Aspergillus spp., including echinocandin- and azole-resistant isolates (2016) (79)
Kucers' The Use of Antibiotics Sixth Edition: A Clinical Review of Antibacterial, Antifungal and Antiviral Drugs (2010) (79)
Flucytosine Resistance Is Restricted to a Single Genetic Clade of Candida albicans (2004) (78)
Therapy and outcome of Candida glabrata versus Candida albicans bloodstream infection. (2008) (78)
Cloning and Characterization of a Complex DNA Fingerprinting Probe for Candida parapsilosis (2001) (77)
Restriction fragment analysis of a Candida tropicalis outbreak of sternal wound infections (1991) (76)
Evaluation and characterization of multiresistant Enterococcus faecium from 12 U.S. medical centers (1994) (76)
A review of the in vitro activity of meropenem and comparative antimicrobial agents tested against 30,254 aerobic and anaerobic pathogens isolated world wide. (1997) (75)
Cross-Resistance between Fluconazole and Ravuconazole and the Use of Fluconazole as a Surrogate Marker To Predict Susceptibility and Resistance to Ravuconazole among 12,796 Clinical Isolates of Candida spp (2004) (75)
Activities of E1210 and Comparator Agents Tested by CLSI and EUCAST Broth Microdilution Methods against Fusarium and Scedosporium Species Identified Using Molecular Methods (2011) (74)
AWARE Ceftaroline Surveillance Program (2008-2010): trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States. (2012) (74)
In vitro activity of meropenem/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem/vaborbactam surveillance programme. (2018) (74)
Variations in DNA subtype, antifungal susceptibility, and slime production among clinical isolates of Candida parapsilosis. (1995) (74)
Methodologies for in vitro and in vivo evaluation of efficacy of antifungal and antibiofilm agents and surface coatings against fungal biofilms (2018) (74)
Evaluation of Three Molecular Typing Techniques for Nonfermentative Gram-Negative Bacilli (2004) (74)
Persistence of Legionella Pneumophila in a Hospital's Water System: A 13-Year Survey (1999) (74)
Significance of Molecular Identification and Antifungal Susceptibility of Clinically Significant Yeasts and Moulds in a Global Antifungal Surveillance Programme (2012) (73)
Genetic relatedness of multidrug-resistant, methicillin (oxacillin)-resistant Staphylococcus aureus bloodstream isolates from SENTRY Antimicrobial Resistance Surveillance Centers worldwide, 1998. (2000) (73)
Comparative evaluation of an automated ribotyping instrument versus pulsed-field gel electrophoresis for epidemiological investigation of clinical isolates of bacteria. (1999) (72)
In Vitro Activities of Ravuconazole (BMS-207147) against 541 Clinical Isolates of Cryptococcus neoformans (2000) (72)
Investigation of Candida albicans transmission in a surgical intensive care unit cluster by using genomic DNA typing methods (1995) (72)
Antimicrobial resistance trends in medical centers using carbapenems: report of 1999 and 2000 results from the MYSTIC program (USA). (2001) (71)
Antifungal dynamics of LY 303366, an investigational echinocandin B analog, against Candida ssp. (1996) (71)
In Vitro Activity of a New Oral Glucan Synthase Inhibitor (MK-3118) Tested against Aspergillus spp. by CLSI and EUCAST Broth Microdilution Methods (2012) (71)
Frequency of fks Mutations among Candida glabrata Isolates from a 10-Year Global Collection of Bloodstream Infection Isolates (2013) (71)
Decreasing Prevalence of β-Lactamase Production among Respiratory Tract Isolates of Haemophilus influenzae in the United States (2005) (71)
The use and abuse of routine stool microbiology: a College of American Pathologists Q-probes study of 601 institutions. (1996) (71)
Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012–15) (2017) (71)
Epidemiological typing methods for mycoses. (1992) (70)
Assigning responsibility: using feedback to achieve sustained control of methicillin-resistant Staphylococcus aureus. (1991) (70)
Evaluation of the in vitro activity of daptomycin against 19615 clinical isolates of Gram-positive cocci collected in North American hospitals (2002-2005). (2007) (70)
Molecular subtypes and antifungal susceptibilities of serial Cryptococcus neoformans isolates in human immunodeficiency virus-associated Cryptococcosis. Cryptococcal Disease Active Surveillance Group. (1996) (69)
Antifungal susceptibility testing. New technology and clinical applications. (2001) (69)
Francisella and Brucella. (2006) (69)
Caspofungin Etest Susceptibility Testing of Candida Species: Risk of Misclassification of Susceptible Isolates of C. glabrata and C. krusei when Adopting the Revised CLSI Caspofungin Breakpoints (2012) (69)
Rapid Detection of Antimicrobial-Resistant Organism Carriage: an Unmet Clinical Need (2004) (69)
Ceftolozane-Tazobactam Activity against Pseudomonas aeruginosa Clinical Isolates from U.S. Hospitals: Report from the PACTS Antimicrobial Surveillance Program, 2012 to 2015 (2017) (68)
In Vitro Activity of Delafloxacin against Contemporary Bacterial Pathogens from the United States and Europe, 2014 (2017) (68)
A Prolonged Outbreak of Methicillin-Resistant Staphylococcus aureus in the Burn Unit of a Tertiary Medical Center (1996) (67)
Respiratory tract pathogens isolated from patients hospitalized with suspected pneumonia: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997). (2000) (67)
Comparison of the Broth Microdilution (BMD) Method of the European Committee on Antimicrobial Susceptibility Testing with the 24-Hour CLSI BMD Method for Testing Susceptibility of Candida Species to Fluconazole, Posaconazole, and Voriconazole by Use of Epidemiological Cutoff Values (2011) (67)
Antifungal susceptibility of South African oral yeast isolates from HIV/AIDS patients and healthy individuals. (2002) (67)
Incidence of invasive aspergillosis among allogeneic hematopoietic stem cell transplant patients receiving voriconazole prophylaxis. (2006) (67)
In Vitro Activity of a Novel Broad-Spectrum Antifungal, E1210, Tested against Aspergillus spp. Determined by CLSI and EUCAST Broth Microdilution Methods (2011) (66)
Two-year assessment of the pathogen frequency and antimicrobial resistance patterns among organisms isolated from skin and soft tissue infections in Latin American hospitals: results from the SENTRY antimicrobial surveillance program, 1997-98. SENTRY Study Group. (2000) (66)
Comparison of pulsed-field gel electrophoresis with isoenzyme profiles as a typing system for Candida tropicalis. (1993) (66)
Comparison of EUCAST and CLSI broth microdilution methods for the susceptibility testing of 10 systemically active antifungal agents when tested against Candida spp. (2014) (66)
Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B against Cryptococcus neoformans. (1998) (66)
Evaluation of the Etest and Disk Diffusion Methods for Determining Susceptibilities of 235 Bloodstream Isolates of Candida glabrata to Fluconazole and Voriconazole (2003) (66)
Unusual Fungal and Pseudofungal Infections of Humans (2005) (65)
Multisite reproducibility of colorimetric broth microdilution method for antifungal susceptibility testing of yeast isolates (1994) (65)
Clinical Evaluation of the Sensititre YeastOne Colorimetric Antifungal Panel for Antifungal Susceptibility Testing of the Echinocandins Anidulafungin, Caspofungin, and Micafungin (2008) (65)
Comparison of the Vitek Gram-Positive Susceptibility 106 Card and the MRSA-Screen Latex Agglutination Test for Determining Oxacillin Resistance in Clinical Bloodstream Isolates of Staphylococcus aureus (2001) (65)
Candida tropicalis vertebral osteomyelitis: a late sequela of fungemia. (1994) (65)
Effectiveness of Anidulafungin in Eradicating Candida Species in Invasive Candidiasis (2005) (65)
Comparison of the Sensititre YeastOne colorimetric antifungal panel with CLSI microdilution for antifungal susceptibility testing of the echinocandins against Candida spp., using new clinical breakpoints and epidemiological cutoff values. (2012) (64)
Wild-type MIC distributions and epidemiologic cutoff values for fluconazole, posaconazole, and voriconazole when testing Cryptococcus neoformans as determined by the CLSI broth microdilution method. (2011) (64)
Antileishmanial Effect of Allopurinol (1974) (64)
Evidence for recombination in Candida glabrata. (2005) (64)
Macrolide and Fluoroquinolone (Levofloxacin) Resistances amongStreptococcus pneumoniae Strains: Significant Trends from the SENTRY Antimicrobial Surveillance Program (North America, 1997–1999) (2000) (64)
Hepatitis C Virus Viremia in HIV‐Infected Individuals With Negative HCV Antibody Tests (2002) (63)
Triazole and Echinocandin MIC Distributions with Epidemiological Cutoff Values for Differentiation of Wild-Type Strains from Non-Wild-Type Strains of Six Uncommon Species of Candida (2011) (63)
Evaluation of Etest Method for Determining Caspofungin (MK-0991) Susceptibilities of 726 Clinical Isolates of CandidaSpecies (2001) (62)
Rapid detection of antibiotic-resistant organism carriage for infection prevention. (2013) (62)
Clinical Evaluation of the Sensititre YeastOne Colorimetric Antifungal Plate for Antifungal Susceptibility Testing of the New Triazoles Voriconazole, Posaconazole, and Ravuconazole (2004) (62)
Evidence of nosocomial spread of Candida albicans causing bloodstream infection in a neonatal intensive care unit. (1995) (62)
A 1994-95 survey of Haemophilus influenzae susceptibility to ten orally administered agents. A 187 clinical laboratory center sample in the United States. (1997) (62)
Activity of echinocandins and triazoles against a contemporary (2012) worldwide collection of yeast and moulds collected from invasive infections. (2014) (62)
Wild-Type MIC Distributions and Epidemiological Cutoff Values for Posaconazole and Voriconazole and Candida spp. as Determined by 24-Hour CLSI Broth Microdilution (2010) (61)
Selection of candidate quality control isolates and tentative quality control ranges for in vitro susceptibility testing of yeast isolates by National Committee for Clinical Laboratory Standards proposed standard methods (1994) (61)
Use of the Appropriateness Evaluation Protocol for Estimating the Incremental Costs Associated With Nosocomial Infections (1987) (61)
Antimicrobial Activities of Aztreonam-Avibactam and Comparator Agents against Contemporary (2016) Clinical Enterobacteriaceae Isolates (2017) (60)
Statistical Analyses of Correlation between Fluconazole MICs for Candida spp. Assessed by Standard Methods Set Forth by the European Committee on Antimicrobial Susceptibility Testing (E.Dis. 7.1) and CLSI (M27-A2) (2006) (60)
Application of new technology to the detection, identification, and antimicrobial susceptibility testing of mycobacteria. (1994) (60)
Improving typeability of multiple bacterial species using pulsed-field gel electrophoresis and thiourea. (2003) (60)
The prevalence of fluoroquinolone resistance among clinically significant respiratory tract isolates of Streptococcus pneumoniae in the United States and Canada--1997 results from the SENTRY Antimicrobial Surveillance Program. (1998) (59)
Use of Epidemiological Cutoff Values To Examine 9-Year Trends in Susceptibility of Candida Species to Anidulafungin, Caspofungin, and Micafungin (2010) (59)
Multisite reproducibility of the Etest MIC method for antifungal susceptibility testing of yeast isolates (1996) (59)
Nosocomial Candidemia: An Ounce of Prevention Is Better Than a Pound of Cure (2004) (59)
DNA subtypes and fluconazole susceptibilities of Candida albicans isolates from the oral cavities of patients with AIDS. (1995) (59)
Selection of a Surrogate Agent (Fluconazole or Voriconazole) for Initial Susceptibility Testing of Posaconazole against Candida spp.: Results from a Global Antifungal Surveillance Program (2007) (59)
Candida Species: Emerging Hospital Bloodstream Pathogens (1991) (58)
Differential Activity of the Oral Glucan Synthase Inhibitor SCY-078 against Wild-Type and Echinocandin-Resistant Strains of Candida Species (2017) (58)
Integration of molecular characterization of microorganisms in a global antimicrobial resistance surveillance program. (2001) (57)
In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Candida spp. as determined by CLSI broth microdilution method. (2011) (57)
Clonal relationships among high-level penicillin-resistant Streptococcus pneumoniae in the United States. (1998) (56)
Antimicrobial resistance in viridans group streptococci among patients with and without the diagnosis of cancer in the USA, Canada and Latin America. (2001) (56)
In vitro susceptibility testing and DNA typing of Saccharomyces cerevisiae clinical isolates (1996) (56)
Characterization of Heteroresistance to Fluconazole among Clinical Isolates of Cryptococcus neoformans (2003) (56)
Five-Year Summary of In Vitro Activity and Resistance Mechanisms of Linezolid against Clinically Important Gram-Positive Cocci in the United States from the LEADER Surveillance Program (2011 to 2015) (2017) (56)
Temporal and Geographic Variation in Antimicrobial Susceptibility and Resistance Patterns of Enterococci: Results From the SENTRY Antimicrobial Surveillance Program, 1997–2016 (2019) (55)
Use of Anidulafungin as a Surrogate Marker To Predict Susceptibility and Resistance to Caspofungin among 4,290 Clinical Isolates of Candida by Using CLSI Methods and Interpretive Criteria (2014) (55)
Antifungal susceptibilities of Candida, Cryptococcus neoformans and Aspergillus fumigatus from the Asia and Western Pacific region: data from the SENTRY antifungal surveillance program (2010–2012) (2015) (55)
Decreased susceptibility of Candida albicans to azole antifungals: a complication of long-term treatment in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) patients. (2007) (54)
Update on antifungal resistance. (1997) (53)
Lot-to-lot variability of antibiotic medium 3 used for testing susceptibility of Candida isolates to amphotericin B (1997) (53)
Prospective Comparison of Whole-Blood- and Plasma-Based Hepatitis C Virus RNA Detection Systems: Improved Detection Using Whole Blood as the Source of Viral RNA (1999) (53)
Implications of acquired oxacillin resistance in the management and control of Staphylococcus aureus infections. (1988) (53)
Evaluation of Endpoints for Antifungal Susceptibility Determinations with LY303366 (1998) (52)
First Description of Klebsiella pneumoniae Harboring CTX-M β-Lactamases (CTX-M-14 and CTX-M-3) in Taiwan (2002) (52)
Prevalence of antimicrobial resistance among respiratory tract isolates in Latin America: results from SENTRY antimicrobial surveillance program (1997-98). (2000) (52)
Susceptibility Test Methods: Yeasts and Filamentous Fungi* (2011) (52)
CD101, a long-acting echinocandin, and comparator antifungal agents tested against a global collection of invasive fungal isolates in the SENTRY 2015 Antifungal Surveillance Program. (2017) (52)
Quality control guidelines for National Committee for Clinical Laboratory Standards--recommended broth macrodilution testing of ketoconazole and itraconazole (1996) (51)
Prevalence of important pathogens and the antimicrobial activity of parenteral drugs at numerous medical centers in the United States. II. Study of the intra- and interlaboratory dissemination of extended-spectrum beta-lactamase-producing Enterobacteriaceae. (1994) (51)
Cefepime MIC as a Predictor of the Extended-Spectrum β-Lactamase Type in Klebsiella pneumoniae, Taiwan (2002) (51)
Surveillance of Omadacycline Activity Tested against Clinical Isolates from the United States and Europe as Part of the 2016 SENTRY Antimicrobial Surveillance Program (2018) (50)
Molecular Epidemiology of Macrolide Resistance in Neonatal Bloodstream Isolates of Group B Streptococci (2003) (50)
Evaluation of Etest Method for Determining Fluconazole and Voriconazole MICs for 279 Clinical Isolates of Candida Species Infrequently Isolated from Blood (2003) (50)
Evaluation of the Etest Method Using Mueller-Hinton Agar with Glucose and Methylene Blue for Determining Amphotericin B MICs for 4,936 Clinical Isolates of Candida Species (2004) (50)
Use of cellular hydrophobicity, slime production, and species identification markers for the clinical significance of coagulase-negative staphylococcal isolates. (1989) (49)
Surveillance of Omadacycline Activity against Clinical Isolates from a Global Collection (North America, Europe, Latin America, Asia-Western Pacific), 2010-2011 (2017) (49)
Comparison of Results of Fluconazole Disk Diffusion Testing for Candida Species with Results from a Central Reference Laboratory in the ARTEMIS Global Antifungal Surveillance Program (2004) (49)
Antimicrobial activity against strains of Escherichia coli and Klebsiella spp. with resistance phenotypes consistent with an extended-spectrum beta-lactamase in Europe. (2003) (49)
Validation of 24-Hour Fluconazole MIC Readings versus the CLSI 48-Hour Broth Microdilution Reference Method: Results from a Global Candida Antifungal Surveillance Program (2008) (49)
Chlamydia and Chlamydophila. (2006) (49)
Reemergence of epidemic methicillin-resistant Staphylococcus aureus in a general hospital associated with changing staphylococcal strains. (1991) (49)
In Vitro Activity of APX001A (Manogepix) and Comparator Agents against 1,706 Fungal Isolates Collected during an International Surveillance Program in 2017 (2019) (48)
The economic impact of rapid Candida species identification by T2Candida among high-risk patients. (2015) (48)
RESPIRATORY SYNCYTIAL VIRUS INFECTIONS IN ADULT BONE MARROW TRANSPLANT RECIPIENTS (1988) (48)
Cardiovascular surgery prophylaxis. A randomized, controlled comparison of cefazolin and cefuroxime. (1990) (48)
Analysis of ALS5 and ALS6 allelic variability in a geographically diverse collection of Candida albicans isolates. (2007) (48)
Nosocomial streptococcal blood stream infections in the SCOPE Program: species occurrence and antimicrobial resistance. The SCOPE Hospital Study Group. (1997) (48)
The use of biotyping and DNA fingerprinting in typing Candida albicans from hospitalized patients. (1990) (48)
Candidemia surveillance in Iowa: emergence of echinocandin resistance. (2014) (47)
Fluconazole Susceptibility Testing of Cryptococcus neoformans: Comparison of Two Broth Microdilution Methods and Clinical Correlates among Isolates from Ugandan AIDS Patients (1998) (47)
Strain variation among and antifungal susceptibilities of isolates of Candida krusei (1996) (47)
In vitro activity of a new triazole antifungal agent, Sch 56592, against clinical isolates of filamentous fungi (2004) (46)
Quality Control and Reference Guidelines for CLSI Broth Microdilution Method (M38-A Document) for Susceptibility Testing of Anidulafungin against Molds (2007) (46)
Rationale for Reading Fluconazole MICs at 24 Hours Rather than 48 Hours When Testing Candida spp. by the CLSI M27-A2 Standard Method (2008) (46)
Use of macrorestriction analysis to demonstrate interhospital spread of multiresistant Acinetobacter baumannii in São Paulo, Brazil. (1996) (46)
Isavuconazole and Nine Comparator Antifungal Susceptibility Profiles for Common and Uncommon Candida Species Collected in 2012: Application of New CLSI Clinical Breakpoints and Epidemiological Cutoff Values (2014) (46)
Performance accuracy of antibacterial and antifungal susceptibility test methods: report from the College of American Pathologists Microbiology Surveys Program (2001-2003). (2006) (46)
In vitro susceptibility testing of filamentous fungi: comparison of Etest and reference M38-A microdilution methods for determining posaconazole MICs. (2003) (46)
Variation in Methicillin-Resistant Staphylococcus aureus Occurrence by Geographic Location and Hospital Characteristics (1987) (46)
The use of molecular techniques in the epidemiology and control of infectious diseases. (1995) (45)
Molecular Phylogenetic Analysis of a Geographically and Temporally Matched Set of Candida albicans Isolates from Humans and Nonmigratory Wildlife in Central Illinois (2008) (45)
Uncoupling of oxidative phosphorylation enables Candida albicans to resist killing by phagocytes and persist in tissue (2007) (45)
Use of Micafungin as a Surrogate Marker To Predict Susceptibility and Resistance to Caspofungin among 3,764 Clinical Isolates of Candida by Use of CLSI Methods and Interpretive Criteria (2013) (45)
Analysis of Global Antifungal Surveillance Results Reveals Predominance of Erg11 Y132F Alteration among Azole-Resistant Candida parapsilosis and Candida tropicalis and Country-Specific Isolate Dissemination. (2019) (45)
The usefulness of screening tests for pyuria in combination with culture in the diagnosis of urinary tract infection. (1987) (45)
Donor-to-host transmission of Candida albicans after corneal transplantation. (2002) (45)
Transmission of fluconazole-resistant Candida albicans between patients with AIDS and oropharyngeal candidiasis documented by pulsed-field gel electrophoresis. (1995) (44)
Hepatitis C virus viremia in HIV-infected individuals with negative HCV antibody tests. (2002) (44)
Variations in fluconazole susceptibility and DNA subtyping of multiple Candida albicans colonies from patients with AIDS and oral candidiasis suffering one or more episodes of infection (1997) (43)
Antimicrobial activity of 12 broad-spectrum agents tested against 270 nosocomial blood stream infection isolates caused by non-enteric gram-negative bacilli: occurrence of resistance, molecular epidemiology, and screening for metallo-enzymes. (1997) (43)
Algorithms for detection and identification of fungi. (2006) (43)
In Vitro Activities of BMS-207147 against Over 600 Contemporary Clinical Bloodstream Isolates of Candida Species from the SENTRY Antimicrobial Surveillance Program in North America and Latin America (1999) (43)
Laboratory procedures for the epidemiological analysis of microorganisms. (2006) (43)
Listeria and Erysipelothrix (2020) (43)
Initial treatment and outcome of Candida glabrata versus Candida albicans bloodstream infection. (2009) (43)
Multicenter evaluation of broth microdilution method for susceptibility testing of Cryptococcus neoformans against fluconazole (1996) (43)
Pre-clinical development of antifungal susceptibility test methods for the testing of the novel antifungal agent E1210 versus Candida: comparison of CLSI and European Committee on Antimicrobial Susceptibility Testing methods. (2011) (43)
Comparison of identification systems for Staphylococcus epidermidis and other coagulase-negative Staphylococcus species. (1994) (42)
Clinical Evaluation of the ASTY Colorimetric Microdilution Panel for Antifungal Susceptibility Testing (1998) (42)
Comparison of the Quantum II, API Yeast Ident, and AutoMicrobic systems for identification of clinical yeast isolates (1988) (42)
Reduction of fluconazole susceptibility of Candida albicans in APECED patients due to long-term use of ketoconazole and miconazole (2008) (41)
In vitro pharmacodynamic characteristics of flucytosine determined by time-kill methods. (2000) (41)
Evaluation of the Discriminatory Powers of the Dienes Test and Ribotyping as Typing Methods for Proteus mirabilis (2000) (41)
Activity of a Long-Acting Echinocandin (CD101) and Seven Comparator Antifungal Agents Tested against a Global Collection of Contemporary Invasive Fungal Isolates in the SENTRY 2014 Antifungal Surveillance Program (2017) (41)
Disseminated Fusarium infections in patients following bone marrow transplantation. (1989) (41)
Molecular Epidemiology of Extended-Spectrum β-Lactamase-Producing, Fluoroquinolone-Resistant Isolates of Klebsiella pneumoniae in Taiwan (2002) (41)
Interlaboratory Study of Quality Control Isolates for a Broth Microdilution Method (Modified CLSI M38-A) for Testing Susceptibilities of Dermatophytes to Antifungals (2006) (41)
Imidazole and polyene activity against chloroquine-resistant Plasmodium falciparum. (1981) (41)
Multicenter Study of Anidulafungin and Micafungin MIC Distributions and Epidemiological Cutoff Values for Eight Candida Species and the CLSI M27-A3 Broth Microdilution Method (2013) (41)
Comparison of the Broth Microdilution Methods of the European Committee on Antimicrobial Susceptibility Testing and the Clinical and Laboratory Standards Institute for Testing Itraconazole, Posaconazole, and Voriconazole against Aspergillus Isolates (2011) (40)
Phenotypic detection of mec A-positive staphylococcal blood stream isolates: high accuracy of simple disk diffusion tests. (1996) (40)
Review of in vitro activity of sertaconazole nitrate in the treatment of superficial fungal infections. (2006) (40)
Drug Resistance Is Not Directly Affected by Mating Type Locus Zygosity in Candida albicans (2003) (40)
Comparison of Visual 24-Hour and Spectrophotometric 48-Hour MICs to CLSI Reference Microdilution MICs of Fluconazole, Itraconazole, Posaconazole, and Voriconazole for Candida spp.: a Collaborative Study (2005) (40)
Evidence for Person-to-Person Transmission of Candida lusitaniae in a Neonatal Intensive-Care Unit (1998) (40)
Are United States hospitals following national guidelines for the analysis and presentation of cumulative antimicrobial susceptibility data? (2004) (40)
In vitro antifungal susceptibilities of isolates of Candida spp. and Aspergillus spp. from China to nine systemically active antifungal agents: data from the SENTRY antifungal surveillance program, 2010 through 2012 (2015) (40)
Identification and Susceptibility Profile of Candida fermentati from a Worldwide Collection of Candida guilliermondii Clinical Isolates (2008) (40)
Candida albicans arthritis one year after successful treatment of fungemia in a healthy infant. (1996) (39)
Occurrence of single-point gyrA mutations among ciprofloxacin-susceptible Escherichia coli isolates causing urinary tract infections in Latin America. (2000) (39)
Evaluation of the Etest Method for Determining Voriconazole Susceptibilities of 312 Clinical Isolates ofCandida Species by Using Three Different Agar Media (2000) (39)
Dalbavancin in-vitro activity obtained against Gram-positive clinical isolates causing bone and joint infections in US and European hospitals (2011-2016). (2017) (38)
Antimicrobial activity and in vitro susceptibility test development for cefditoren against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus species. (2000) (38)
Bipolaris, Exophiala, Scedosporium, Sporothrix, and other dematiaceous fungi. (2006) (38)
Evaluation of Etest Method for Determining Voriconazole and Amphotericin B MICs for 162 Clinical Isolates of Cryptococcus neoformans (2003) (38)
Surveillance of the current resistance of nosocomial pathogens to antibacterials (1997) (38)
In Vitro Pharmacodynamic Characteristics of Nystatin Including Time-Kill and Postantifungal Effect (2000) (38)
Optimizing Echinocandin Dosing and Susceptibility Breakpoint Determination via In Vivo Pharmacodynamic Evaluation against Candida glabrata with and without fks Mutations (2012) (38)
Multilaboratory Testing of Two-Drug Combinations of Antifungals against Candida albicans, Candida glabrata, and Candida parapsilosis (2011) (38)
Multicenter comparison of a colorimetric microdilution broth method with the reference macrodilution method for in vitro susceptibility testing of yeast isolates. (1994) (37)
Multicenter Evaluation of the Antimicrobial Activity for Six Broad-Spectrum β-Lactams in Venezuela Using the Etest Method (1998) (37)
Evaluation of DNA-based typing procedures for strain categorization of Candida spp. (1999) (37)
Rhizopus, Rhizomucor, Absidia, and other agents of systemic and subcutaneous zygomycosis (1999) (37)
Collaborative Study of the NCCLS and Flow Cytometry Methods for Antifungal Susceptibility Testing of Candida albicans (2004) (37)
Neisseria meningitidis with decreased susceptibility to penicillin: report from the SENTRY antimicrobial surveillance program, North America, 1998-99. (2001) (37)
Comparison of the Vitek Gram-Positive Susceptibility 106 Card, the MRSA-Screen Latex Agglutination Test, and mecA Analysis for Detecting Oxacillin Resistance in a Geographically Diverse Collection of Clinical Isolates of Coagulase-Negative Staphylococci (2001) (37)
Change in Colony Morphology of Candida lusitaniae in Association with Development of Amphotericin B Resistance (2002) (37)
ZAAPS Program results for 2015: an activity and spectrum analysis of linezolid using clinical isolates from medical centres in 32 countries (2017) (36)
Predictive value of surveillance cultures for systemic infection due toCandida species (1987) (36)
Transmission of herpes simplex virus type 1 infection in an intensive care unit. (1992) (36)
"Gesundheit!" sneezing, common colds, allergies, and Staphylococcus aureus dispersion. (2006) (36)
Antimicrobial activity of gatifloxacin tested against 1676 strains of ciprofloxacin-resistant gram-positive cocci isolated from patient infections in North and South America. (1998) (36)
Methods for estimating days of hospitalization due to nosocomial infections. (1992) (36)
Telavancin activity against Gram-positive bacteria isolated from respiratory tract specimens of patients with nosocomial pneumonia. (2010) (36)
Development of the quantitative micro-test for slime production by coagulase-negative staphylococci (1988) (36)
Geographic variations in garenoxacin (BMS284756) activity tested against pathogens associated with skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (2000). (2002) (36)
In Vitro Activity of Isavuconazole against Opportunistic Fungal Pathogens from Two Mycology Reference Laboratories (2018) (35)
Surveillance of tigecycline activity tested against clinical isolates from a global (North America, Europe, Latin America and Asia-Pacific) collection (2016). (2018) (35)
Clade-related amphotericin B resistance among South African Candida albicans isolates. (2005) (35)
Antifungal susceptibility testing methods. (2005) (35)
Comparison of the Vitek 2 yeast susceptibility system with CLSI microdilution for antifungal susceptibility testing of fluconazole and voriconazole against Candida spp., using new clinical breakpoints and epidemiological cutoff values. (2013) (34)
In Vitro Antifungal Susceptibility Testing (2001) (34)
Carbapenem-resistant Serratia marcescens isolates producing Bush group 2f beta-lactamase (SME-1) in the United States: results from the MYSTIC Programme. (2001) (34)
Microdilution antifungal susceptibility testing of Candida albicans and Cryptococcus neoformans with and without agitation: an eight-center collaborative study (1996) (34)
In vitro interaction of fluconazole and amphotericin B administered sequentially against Candida albicans: effect of concentration and exposure time. (1998) (34)
Infection Control: Opportunistic Fungal Infections—The Increasing Importance of Candida Species (1989) (34)
Oxygen enhances the antimalarial activity of the imidazoles. (1983) (34)
Activity of amphotericin B, anidulafungin, caspofungin, micafungin, posaconazole, and voriconazole against Candida albicans with decreased susceptibility to fluconazole from APECED patients on long-term azole treatment of chronic mucocutaneous candidiasis. (2008) (34)
Evaluation of the NCCLS M44-P Disk Diffusion Method for Determining Susceptibilities of 276 Clinical Isolates of Cryptococcus neoformans to Fluconazole (2004) (34)
Recurrent epidemics caused by a single strain of erythromycin-resistant Staphylococcus aureus. The importance of molecular epidemiology. (1993) (34)
The clinical microbiology laboratory as an aid in infection control. The application of molecular techniques in epidemiologic studies of methicillin-resistant Staphylococcus aureus. (1991) (33)
Recurrent gram-negative bacteremia: incidence and clinical patterns. (1999) (33)
Antimicrobial activity of cefepime tested against ceftazidime-resistant Gram-negative clinical strains from North American Hospitals: report from the SENTRY Antimicrobial Surveillance Program (1998-2004). (2006) (33)
Infection control: the premier quality assessment program in United States hospitals. (1991) (33)
Molecular epidemiology in the care of patients. (1999) (33)
Treponema and other human host-associated spirochetes. (2006) (32)
Analysis of Candida auris fungemia at a single facility in Kenya. (2019) (32)
Activity of dalbavancin and comparator agents against Gram-positive cocci from clinical infections in the USA and Europe 2015–16 (2018) (32)
Anidulafungin: an echinocandin antifungal (2004) (32)
Evaluation of Etest Method for Determining Posaconazole MICs for 314 Clinical Isolates ofCandida Species (2001) (32)
Evaluation of the activity of fusidic acid tested against contemporary Gram-positive clinical isolates from the USA and Canada. (2010) (32)
Activity and spectrum of BMS 284756, a new des-F (6) quinolone, tested against strains of ciprofloxacin-resistant Gram-positive cocci. (2001) (32)
Multicenter Comparison of the Vitek 2 Antifungal Susceptibility Test with the CLSI Broth Microdilution Reference Method for Testing Caspofungin, Micafungin, and Posaconazole against Candida spp (2011) (31)
Comparison of results of fluconazole and voriconazole disk diffusion testing for Candida spp. with results from a central reference laboratory in the ARTEMIS DISK Global Antifungal Surveillance Program. (2009) (31)
Fluoroquinolone-resistant Moraxella catarrhalis in a patient with pneumonia: report from the SENTRY Antimicrobial Surveillance Program (1998). (1998) (31)
Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Latin America: report from an antimicrobial surveillance program (2013–2015) (2017) (31)
Multisite reproducibility of MIC results by the Sensititre YeastOne colorimetric antifungal susceptibility panel. (1998) (31)
Antimicrobial activity of tigecycline and cefoperazone/sulbactam tested against 18,386 Gram-negative organisms from Europe and the Asia-Pacific region (2013-2014). (2017) (31)
An Outbreak of Staphylococcus aureus in a Pediatric Cardiothoracic Surgery Unit (2002) (31)
Impact of rapid, culture-independent diagnosis of candidaemia and invasive candidiasis in a community health system (2018) (31)
Multicenter evaluation of antimicrobial resistance to six broad-spectrum β-lactams in Colombia using the Etest method (1997) (31)
The yeast connection: is Candida linked to breastfeeding associated pain? (2006) (30)
Vancomycin-resistant Enterococcus raffinosus: molecular epidemiology, species identification error, and frequency of occurrence in a national resistance surveillance program. (1997) (30)
Multilaboratory Testing of Antifungal Combinations against a Quality Control Isolate of Candida krusei (2008) (30)
Comparative antimicrobial activity of trovafloxacin tested against 3049 Streptococcus pneumoniae isolates from the 1997-1998 respiratory infection season. (1998) (30)
Activity of Gatifloxacin against Haemophilus influenzae and Moraxella catarrhalis, Including Susceptibility Test Development, E-Test Comparisons, and Quality Control Guidelines for H. influenzae (1999) (30)
Molecular epidemiology and antifungal susceptibility of Cryptococcus neoformans isolates from Ugandan AIDS patients. (1998) (29)
Activities of Omadacycline and Comparator Agents against Staphylococcus aureus Isolates from a Surveillance Program Conducted in North America and Europe (2016) (29)
Ceftaroline activity against bacterial organisms isolated from acute bacterial skin and skin structure infections in United States medical centers (2009-2011). (2014) (29)
Validation of 24-Hour Posaconazole and Voriconazole MIC Readings versus the CLSI 48-Hour Broth Microdilution Reference Method: Application of Epidemiological Cutoff Values to Results from a Global Candida Antifungal Surveillance Program (2011) (29)
A global evaluation of voriconazole activity tested against recent clinical isolates of Candida spp. (2009) (29)
Molecular Epidemiology of Coagulase-Negative Staphylococci Isolated From Immunocompromised Patients (1992) (29)
In vitro efficacy of six cephalosporins tested against Enterobacteriaceae isolated at 38 North American medical centres participating in the SENTRY Antimicrobial Surveillance Program, 1997-1998. (2000) (29)
Confirmation of extended-spectrum beta-lactamase-producing Serratia marcescens: preliminary report from Taiwan. (2003) (29)
Tiamulin Activity against Fastidious and Nonfastidious Veterinary and Human Bacterial Isolates: Initial Development of In Vitro Susceptibility Test Methods (2002) (29)
Activities of Tedizolid and Linezolid Determined by the Reference Broth Microdilution Method against 3,032 Gram-Positive Bacterial Isolates Collected in Asia-Pacific, Eastern Europe, and Latin American Countries in 2014 (2016) (29)
Variation in Electrophoretic Karyotype and Antifungal Susceptibility of Clinical Isolates of Cryptococcus neoformans at a University-Affiliated Teaching Hospital from 1987 to 1994 (1998) (29)
Antimicrobial activity of ceftobiprole and comparator agents when tested against contemporary Gram-positive and -negative organisms collected from Europe (2015). (2018) (28)
Antifungal susceptibility testing. Current state of technology, limitations, and standardization. (1993) (28)
Comparison of the autoSCAN-W/A rapid bacterial identification system and the Vitek AutoMicrobic system for identification of gram-negative bacilli (1991) (28)
Activity of BMS284756 against 2,681 recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis: Report from The SENTRY Antimicrobial Surveillance Program (2000) in Europe, Canada and the United States. (2001) (28)
The use of molecular techniques for epidemiologic typing of Candida species. (1992) (28)
Preventing the Airborne Spread of Staphylococcus aureus by Persons With the Common Cold: Effect of Surgical Scrubs, Gowns, and Masks (2007) (28)
The Epidemiology of Invasive Candidiasis (2012) (28)
Effects of fluconazole on the sterol and carbohydrate composition of four species ofCandida (1992) (28)
Spectrum and activity of three contemporary fluoroquinolones tested against Pseudomonas aeruginosa isolates from urinary tract infections in the SENTRY Antimicrobial Surveillance Program (Europe and the Americas; 2000): more alike than different! (2001) (28)
Frequency of occurrence and antimicrobial susceptibility patterns for pathogens isolated from latin american patients with a diagnosis of pneumonia: results from the SENTRY antimicrobial surveillance program (1998). (2000) (28)
Electrophoretic karyotype and in vitro antifungal susceptibility of Cryptococcus neoformans isolates from AIDS patients. (1995) (28)
Effects of cilofungin (LY121019) on carbohydrate and sterol composition ofCandida albicans (1989) (27)
Candida glabrata Mutants Demonstrating Paradoxical Reduced Caspofungin Susceptibility but Increased Micafungin Susceptibility (2011) (27)
Evaluation of Etest and Disk Diffusion Methods Compared with Broth Microdilution Antifungal Susceptibility Testing of Clinical Isolates of Candida spp. against Posaconazole (2007) (27)
Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa collected from patients with bloodstream infections isolated in United States hospitals (2013-2015) as part of the Program to Assess Ceftolozane-Tazobactam Susceptibility (PACTS) surveillanc (2018) (27)
Rotaviruses, caliciviruses, astroviruses, enteric adenoviruses, and other diarrheic viruses. (2006) (27)
Handwashing: efficacy versus acceptance. A brief essay. (1991) (27)
Evaluation of Disk Diffusion and Etest Compared to Broth Microdilution for Antifungal Susceptibility Testing of Posaconazole against Clinical Isolates of Filamentous Fungi (2007) (27)
Ceftobiprole Activity against Gram-Positive and -Negative Pathogens Collected from the United States in 2006 and 2016 (2018) (27)
Antimicrobial susceptibility of bacteria causing urinary tract infections in Latin American hospitals: results from the SENTRY Antimicrobial Surveillance Program (1997). (1999) (26)
Activity of a Long-Acting Echinocandin, Rezafungin, and Comparator Antifungal Agents Tested against Contemporary Invasive Fungal Isolates (SENTRY Program, 2016 to 2018) (2020) (26)
Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: Results from the SENTRY Antimicrobial Surveillance Programme, 2017. (2019) (26)
Activity of omadacycline tested against Streptococcus pneumoniae from a global surveillance program (2014). (2018) (26)
Stability of Mueller-Hinton Agar Supplemented with Glucose and Methylene Blue for Disk Diffusion Testing of Fluconazole and Voriconazole (2004) (26)
Wild-type minimum effective concentration distributions and epidemiologic cutoff values for caspofungin and Aspergillus spp. as determined by Clinical and Laboratory Standards Institute broth microdilution methods. (2010) (26)
A Head-on Comparison of the In Vitro Antifungal Activity of Conventional and Lipid-based Amphotericin B: a Multicenter Study (2000) (25)
Relapse of catheter-related Flavobacterium meningosepticum bacteremia demonstrated by DNA macrorestriction analysis. (1995) (25)
Value of the Hybritech ICON Candida Assay in the diagnosis of invasive candidiasis in high-risk patients. (1993) (25)
Cefditoren in vitro activity and spectrum: a review of international studies using reference methods. (2001) (25)
Evaluation of CLSI M44-A2 Disk Diffusion and Associated Breakpoint Testing of Caspofungin and Micafungin Using a Well-Characterized Panel of Wild-Type and fks Hot Spot Mutant Candida Isolates (2011) (25)
Therapy of Candida Infections: Susceptibility Testing, Resistance, and Therapeutic Options (1998) (25)
Evaluation of the Vitek system to accurately test the susceptibility of Pseudomonas aeruginosa clinical isolates against cefepime. (1998) (25)
Effects of sucralfate vs antacids on gastric pathogens: results of a double-blind clinical trial. (1998) (25)
Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015). (2017) (25)
Effects of terconazole and other azole antifungal agents on the sterol and carbohydrate composition of Candida albicans. (1990) (24)
Strain variation and antifungal susceptibility among bloodstream isolates of Candida species from 21 different medical institutions. (1995) (24)
In Vitro Activity of Minocycline against U.S. Isolates of Acinetobacter baumannii-Acinetobacter calcoaceticus Species Complex, Stenotrophomonas maltophilia, and Burkholderia cepacia Complex: Results from the SENTRY Antimicrobial Surveillance Program, 2014 to 2018 (2019) (24)
Antimicrobial activity evaluations of gatifloxacin, a new fluoroquinolone: contemporary pathogen results from a global antimicrobial resistance surveillance program (SENTRY, 1997). (1999) (24)
Growth medium effect on the antifungal activity of LY 303366. (1997) (24)
Use of Molecular and Reference Susceptibility Testing Methods in a Multicenter Evaluation of MicroScan Dried Overnight Gram-Positive MIC Panels for Detection of Vancomycin and High-Level Aminoglycoside Resistances in Enterococci (1998) (24)
Antimicrobial activity and spectrum investigation of eight broad-spectrum beta-lactam drugs: a 1997 surveillance trial in 102 medical centers in the United States. Cefepime Study Group. (1998) (24)
The application of molecular and immunologic techniques to study the epidemiology of Legionella pneumophila serogroup 1. (1989) (24)
Can antimicrobial susceptibility testing results for ciprofloxacin or levofloxacin predict susceptibility to a newer fluoroquinolone, gatifloxacin?: Report from The SENTRY Antimicrobial Surveillance Program (1997-99). (2001) (24)
Posaconazole MIC Distributions for Aspergillus fumigatus Species Complex by Four Methods: Impact of cyp51A Mutations on Estimation of Epidemiological Cutoff Values (2018) (24)
Modification of Dienes Mutual Inhibition Test for Epidemiological Characterization of Pseudomonas aeruginosa Isolates (2002) (23)
Assessment of laboratory performance with Streptococcus pneumoniae antimicrobial susceptibility testing in the United States: a report from the College of American Pathologists Microbiology Proficiency Survey Program. (1999) (23)
The epidemiology of invasive mycoses--narrowing the gap. (1998) (23)
Multicenter evaluation of the antimicrobial activity for six broad-spectrum β-lactams in Venezuela: comparison of data from 1997 and 1998 using the Etest method (1999) (23)
In vitro activity of ceftiofur tested against clinical isolates of Escherichia coli and Klebsiella pneumoniae including extended spectrum beta-lactamase producing strains. (2000) (23)
Surveillance of Omadacycline Activity Tested against Clinical Isolates from the United States and Europe: Report from the SENTRY Antimicrobial Surveillance Program, 2016 to 2018 (2020) (23)
In vitro activity of selected cephalosporins and erythromycin against staphylococci and pneumococci isolated at 38 North American medical centers participating in the SENTRY Antimicrobial Surveillance Program, 1997-1998. (2000) (23)
Comparison of an Automated Ribotyping System to Restriction Endonuclease Analysis and Pulsed-Field Gel Electrophoresis for Differentiating Vancomycin-Resistant Enterococcus faecium Isolates (2002) (22)
Biotyping of coagulase-negative staphylococci. 108 isolates from nosocomial bloodstream infections. (1990) (22)
Role of molecular epidemiology in infection control. (1997) (22)
Antifungal activity of a new triazole, D0870, compared with four other antifungal agents tested against clinical isolates of Candida and Torulopsis glabrata. (1994) (22)
Bacterial and fungal pathogens isolated from patients with bloodstream infection: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (2012-2017). (2020) (21)
Antimicrobial susceptibility of inducible AmpC beta-lactamase-producing Enterobacteriaceae from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme, Europe 1997-2000. (2002) (21)
Airborne Dispersal as a Novel Transmission Route of Coagulase-Negatwe Staphylococci Interaction Between Coagulase-Negative Staphylococci and Rhinovirus Infection (2004) (21)
Emergence of Two Klebsiella pneumoniae Isolates Harboring Plasmid-Mediated CTX-M-15 β-Lactamase in Taiwan (2004) (21)
Effect of serum on the in vitro activities of 11 broad-spectrum antibiotics (1990) (21)
Accuracy of the Vitek system for antimicrobial susceptibility testing Enterobacteriaceae bloodstream infection isolates: use of "direct" inoculation from Bactec 9240 blood culture bottles. (1997) (21)
Multicenter evaluation of the antimicrobial activity for seven broad-spectrum beta-lactams in Turkey using the Etest method. Turkish Antimicrobial Resistance Study Group. (1999) (21)
Comparative antimicrobial activity of gatifloxacin tested against Streptococcus spp. including quality control guidelines and etest method validation. Quality Control Study Group. (1999) (21)
Multicenter evaluation of antimicrobial resistance to six broad-spectrum β-lactams in Colombia: comparison of data from 1997 and 1998 using the Etest method☆ (1999) (20)
Susceptibility of nosocomial isolates of Candida species to LY121019 and other antifungal agents. (1989) (20)
Specimen collection, transport, and processing: mycology. (2006) (20)
In vitro activity of cefepime and ceftazidime against 197 nosocomial blood stream isolates of streptococci: a multicenter sample. (1997) (20)
Antimicrobial Activity of Dalbavancin against Staphylococcus aureus with Decreased Susceptibility to Glycopeptides, Daptomycin, and/or Linezolid from U.S. Medical Centers (2017) (20)
Cefdinir (FK482), an orally administered cephalosporin in vitro activity comparison against recent clinical isolates from five medical centers and determination of MIC quality control guidelines. (1992) (20)
Multicenter Evaluation of the New Vitek 2 Yeast Susceptibility Test Using New CLSI Clinical Breakpoints for Fluconazole (2014) (20)
Restriction Endonuclease Analysis of Plasmid DNA From Methicillin-Resistant Staphylococcus aureus: Clinical Application Over a Three-Year Period (1993) (20)
Transmission of Citrobacter koseri from mother to infant documented by ribotyping and pulsed-field gel electrophoresis. (1996) (19)
Antimicrobial Susceptibility Testing of Clinical Isolates of Bordetella pertussis from Northern California: Report from the SENTRY Antimicrobial Surveillance Program (2001) (19)
Comparison of the activity of two broad-spectrum cephalosporins tested against 2,299 strains of Pseudomonas aeruginosa isolated at 38 North American medical centers participating in the SENTRY Antimicrobial Surveillance Program, 1997-1998. (2000) (19)
Use of Penicillin MICs To Predict In Vitro Activity of Other β-Lactam Antimicrobial Agents againstStreptococcus pneumoniae (2001) (18)
Laboratory aids in the diagnosis of invasive candidiasis (1992) (18)
Infection Control Epidemiology and Clinical Microbiology (2011) (18)
Oritavancin in vitro activity against gram-positive organisms from European and United States medical centers: results from the SENTRY Antimicrobial Surveillance Program for 2010-2014. (2018) (18)
Manual of clinical microbiology: Volume 1. (2006) (18)
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) (2010) (18)
Epidemiology of Methicillin-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococcus in a Rural State (2006) (18)
Antifungal susceptibility testing: progress and future developments. (2000) (18)
Phenotypic and genotypic characterizations of chinese strains of Escherichia coli producing extended-spectrum β-lactamases (1999) (18)
Variations in DNA subtype and antifungal susceptibility among clinical isolates of Candida tropicalis. (1997) (18)
Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Australia and New Zealand: Report from an Antimicrobial Surveillance Program (2013-2015). (2017) (18)
Comparison of Genomic Methods for Differentiating Strains of Enterococcus faecium: Assessment Using Clinical Epidemiologic Data (1998) (17)
Activity of omadacycline tested against Enterobacteriaceae causing urinary tract infections from a global surveillance program (2014). (2018) (17)
DNA macrorestriction profiles and antifungal susceptibility of Candida (Torulopsis) glabrata. (1996) (17)
Update on Clinical Antifungal Susceptibility Testing for Candida Species (1998) (17)
Ceftobiprole activity when tested against contemporary bacteria causing bloodstream infections in the United States (2016-2017). (2019) (17)
Genotypic characterization of carbapenem-nonsusceptible Acinetobacter spp. isolated in Latin America. (2004) (17)
Influence of in vitro susceptibility testing conditions on the anti-candidal activity of LY121019. (1988) (17)
Antimicrobial activity of dalbavancin tested against Gram-positive organisms isolated from patients with infective endocarditis in US and European medical centres (2019) (17)
Agents of Zygomycosis (2003) (17)
Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Contemporary (2015-2017) P. aeruginosa Isolates from a Global Surveillance Program. (2020) (17)
Use of rapid screening tests in processing urine specimens by conventional culture and the AutoMicrobic system (1985) (17)
Gatifloxacin phase IV surveillance trial (TeqCES study) utilizing 5000 primary care physician practices: report of pathogens isolated and susceptibility patterns in community-acquired respiratory tract infections. (2002) (16)
Molecular epidemiology of gram-negative bacteremia. (1999) (16)
Investigation of foodborne and waterborne disease outbreaks. (2006) (16)
Screening of a Large Global Aspergillus fumigatus Species Complex Collection by Using a Species-Specific Microsphere-Based Luminex Assay (2009) (16)
United States geographic bacteria susceptibility patterns (1999) (16)
Molecular epidemiology of coagulase-negative staphylococci isolated from immunocompromised patients. (1992) (16)
Evaluation of Synergistic Activity of Isavuconazole or Voriconazole plus Anidulafungin and the Occurrence and Genetic Characterization of Candida auris Detected in a Surveillance Program (2021) (16)
Evaluation of growth characteristics on blood agar and eosin methylene blue agar for the identification of Candida (Torulopsis) glabrata. (1997) (16)
Comparison of expression of virulence factors by Escherichia coli causing cystitis and E. coli colonizing the periurethra of healthy girls. (1995) (16)
Activity of tedizolid against gram-positive clinical isolates causing infections in Europe and surrounding areas (2014–2015) (2019) (16)
Feasible and desirable future targets for reducing the costs of hospital infections. (1991) (16)
Comparative antistreptococcal activity of two newer fluoroquinolones, levofloxacin and sparfloxacin. (1997) (16)
Vitek GPS card susceptibility testing accuracy using direct inoculation from BACTEC 9240 blood culture bottles. (1996) (15)
A Cluster of Serious Escherichia coli Infections in a Neonatal Intensive-Care Unit (1997) (15)
Colony morphology of Candida spp. as a guide to species identification. (1999) (15)
Epidemiology of polyclonal gram-negative bacteremia. (1998) (15)
CHAPTER 1 – The epidemiology of fungal infections (2009) (15)
Activity of Ketoconazole and Its Deacyl Derivative Against Plasmodium falciparum and Candida Isolates (1982) (15)
Clinical Evaluation of a Frozen Commercially Prepared Microdilution Panel for Antifungal Susceptibility Testing of Seven Antifungal Agents, Including the New Triazoles Posaconazole, Ravuconazole, and Voriconazole (2002) (15)
Wild-Type MIC Distributions and Epidemiologic Cutoff Values for Fluconazole and Candida: Time for New Clinical Breakpoints? (2010) (14)
Performance of Fusidic Acid (CEM-102) Susceptibility Testing Reagents: Broth Microdilution, Disk Diffusion, and Etest Methods as Applied to Staphylococcus aureus (2010) (14)
Airborne dispersal of Staphylococcus aureus associated with symptomatic rhinitis allergica. (2003) (14)
Polyamine depletion and growth inhibition in Candida albicans and Candida tropicalis by alpha-difluoromethylornithine and cyclohexylamine. (1988) (14)
Epidemiology of nosocomial candidiasis: the importance of molecular typing. (2000) (14)
Activity of ceftolozane-tazobactam and comparators when tested against Gram-negative isolates collected from paediatric patients in the USA and Europe between 2012 and 2016 as part of a global surveillance programme. (2019) (13)
Kucers' The Use of Antibiotics (2010) (13)
Frequency and antimicrobial susceptibility of bacterial isolates from patients hospitalised with community-acquired skin and skin-structure infection in Europe, Asia and Latin America. (2019) (13)
Clinical evaluation of a dried commercially-prepared microdilution panel for antifungal susceptibility testing. (1996) (13)
Ceftaroline Activity Tested against Bacterial Isolates Causing Community-Acquired Respiratory Tract Infections and Skin and Skin Structure Infections in Pediatric Patients from United States Hospitals: 2012-2014. (2017) (13)
Disseminated histoplasmosis presenting as an acute tenosynovitis. (1985) (13)
Nosocomial Candida infections (1988) (13)
BMS284756 (formerly T-3811, a des-fluoroquinolone) potency and spectrum tested against over 10,000 bacterial bloodstream infection isolates from the SENTRY antimicrobial surveillance programme (2000). (2002) (13)
Ceftaroline Activity Against Multidrug-Resistant Streptococcus pneumoniae from U.S. Medical Centers (2014) and Molecular Characterization of a Single Ceftaroline Nonsusceptible Isolate. (2017) (13)
Application of a biotyping system and DNA restriction fragment analysis to the study of Serratia marcescens from hospitalized patients. (1993) (13)
Evaluation of gemifloxacin (SB-265805, LB20304a): in vitro activity against over 6000 gram-positive pathogens from diverse geographic areas. (2000) (13)
Candida glabrata: Multidrug Resistance and Increased Virulence in a Major Opportunistic Fungal Pathogen (2012) (12)
Ehrlichia, Anaplasma, and related intracellular bacteria. (2006) (12)
Multicenter Evaluation of the In Vitro Activity of Six Broad-Spectrum β-Lactam Antimicrobial Agents in Puerto Rico (1998) (12)
Comparative antimicrobial spectrum and activity of BMS284756 (T-3811, a desfluoroquinolone) tested against 656 Enterobacteriaceae, including preliminary in vitro susceptibility test comparisons and development. (2001) (12)
Ciprofloxacin as broad-spectrum empiric therapy--are fluoroquinolones still viable monotherapeutic agents compared with beta-lactams: data from the MYSTIC Program (US)? (2002) (12)
Application of restriction endonuclease analysis of chromosomal DNA in the study of Staphylococcus aureus colonization in continuous ambulatory peritoneal dialysis patients. (1992) (12)
Comparison of the Quantum II Bacterial Identification System and the AutoMicrobic System for the identification of gram-negative bacilli (1986) (12)
Antimicrobial Activity of First-in-Class Antifungal, Manogepix, and Comparator Agents Testing against Contemporary Invasive Fungal Isolates from an International Surveillance Program (2018-2019): In Vitro Activity of Manogepix against Fungal Isolates. (2021) (12)
Application of Culture-Independent Rapid Diagnostic Tests in the Management of Invasive Candidiasis and Cryptococcosis (2015) (12)
In Vitro Activities of Ceftaroline and Comparators against Streptococcus pneumoniae Isolates from U.S. Hospitals: Results from Seven Years of the AWARE Surveillance Program (2010 to 2016) (2017) (12)
Strain Variation Among Candida Species: Application of Various Typing Methods to Study the Epidemiology and Pathogenesis of Candidiasis in Hospitalized Patients (1987) (12)
Quality Control Limits for Fluconazole Disk Susceptibility Tests on Mueller-Hinton Agar with Glucose and Methylene Blue (2003) (12)
Standardization of antifungal susceptibility testing. (1996) (11)
Use of plasmid profiles and restriction endonuclease analysis of plasmid DNA as epidemiologic and diagnostic tools in the clinical microbiology laboratory (1989) (11)
Comparison of Porphyrin-Based, Growth Factor-Based, and Biochemical-Based Testing Methods for Identification of Haemophilus influenzae (2002) (11)
Comparison of Results Generated by Serotyping, Pulsed-Field Restriction Analysis, Ribotyping, and Repetitive-Sequence PCR Used To Characterize Penicillin-Resistant Pneumococci from the United States (2001) (11)
In-vitro susceptibility of nosocomial gram-negative bloodstream pathogens to quinolones and other antibiotics--a statistical approach. (1989) (11)
In-vitro activities of gatifloxacin, sparfloxacin and trovafloxacin against 103 strains of Legionella spp. (1998) (11)
Antifungal drug susceptibility testing. (1994) (11)
Hepatitis C and G viruses. (2006) (11)
Molecular epidemiology of gastric colonization by Enterococcus faecalis in a surgical intensive care unit. (1994) (10)
Oral β-lactams in the treatment of acute bacterial rhinosinusitis (2007) (10)
Multicenter evaluation of antimicrobial resistance to six broad-spectrum beta-lactams in Colombia: comparison of data from 1997 and 1998 using the Etest method. The Colombian Antimicrobial Resistance Study Group. (1999) (10)
Clinical evaluation of a dried commercially prepared microdilution panel for antifungal susceptibility testing of five antifungal agents against Candida spp. and Cryptococcus neoformans. (2004) (10)
Evaluation of the discriminatory power of pulsed-field gel electrophoresis and PCR fingerprinting for epidemiologic typing of Candida species. (1998) (10)
In vitro evaluation of contemporary β-lactam drugs tested against viridans group and β-haemolytic streptococci (1997) (10)
Telavancin Activity Against Gram-Positive Bacteria Isolated from Patients with Skin and Skin-Structure Infections (2010) (10)
Ability of the Modified Vitek Card To Detect Coagulase-Negative Staphylococci with mecA and Oxacillin-Resistant Phenotypes (1999) (10)
Investigation of suspected nosocomial clusters of Staphylococcus haemolyticus infections. (1999) (10)
Multi-center evaluation of antifungal time-kill methods (2001) (9)
Prevention of Health Care-Associated Infections (2015) (9)
Multicenter evaluation of the antimicrobial activity for six broad-spectrum beta-lactams in Venezuela: comparison of data from 1997 and 1998 using the Etest method. Venezuelan Antimicrobial Resistance Study Group. (1999) (9)
New developments in the antifungal susceptibility testing of Candida (2008) (9)
Activity of dalbavancin tested against Gram-positive clinical isolates causing skin and skin-structure infections in paediatric patients from US hospitals (2014-2015). (2017) (9)
In Vitro Activity of Telavancin Against Clinically Important Gram-Positive Pathogens from 69 U.S. Medical Centers (2015): Potency Analysis by U.S. Census Divisions (2017) (9)
Invasive Fungal Infections and Approaches to Their Diagnosis (2015) (9)
Molecular epidemiology and antimicrobial susceptibility testing. Testing of quinolone-resistant Staphylococcus aureus strains isolated in Brazil. (1993) (9)
Use of antimicrobial susceptibility testing for epidemiology and the selection of oral, parenteral and topical regimens for control of CAPD-associated Staphylococcus aureus infection. (1991) (9)
Ceftobiprole Activity against Bacteria from Skin and Skin Structure Infections in the United States from 2016 through 2018 (2020) (9)
In Vitro Activity of Tedizolid in Comparison with Other Oral and Intravenous Agents Against a Collection of Community-Acquired Methicillin-Resistant Staphylococcus aureus (2014-2015) in the United States. (2019) (9)
Gatifloxacin (AM-1155, CG 5501) susceptibility testing interpretive criteria and quality control guidelines for dilution and disk (5-μg) diffusion methods (1999) (9)
DiskDiffusion Testing Using Candida sp. Colonies Taken Directlyfrom CHROMagar Candida Medium May Decrease Time Required To ObtainResults (2005) (9)
In Vitro Activity of KBP-7072, a Novel Third-Generation Tetracycline, against 531 Recent Geographically Diverse and Molecularly Characterized Acinetobacter baumannii Species Complex Isolates (2020) (9)
Infection control: opportunistic fungal infections--the increasing importance of Candida species. (1989) (9)
Chapter 10 – Infections caused by non-Candida, non-Cryptococcus yeasts (2009) (9)
In vitro comparison of GR69153, a novel catechol-substituted cephalosporin, with ceftazidime and ceftriaxone against 5,203 recent clinical isolates (1991) (9)
Molecular epidemiology for local outbreaks of methicillin resistantStaphylococcus aureus (MRSA) (1994) (9)
Clinical evaluation of a direct fluorescent monoclonal antibody test for detection of Pseudomonas aeruginosa in blood cultures (1989) (8)
Risk Factors for Hospital-Acquired Candidemia (2017) (8)
Quality Control Limits for Voriconazole Disk Susceptibility Tests on Mueller-Hinton Agar with Glucose and Methylene Blue (2004) (8)
Drug Resistance in Cryptococcus: Epidemiology and Molecular Mechanisms (2011) (8)
Value of the Candida antigen assay in diagnosis of systemic candidiasis in burn patients. (1992) (8)
Quality control guidelines for Haemophilus test medium MIC susceptibility tests with cefmetazole, cefpodoxime, CI-960 (PD127391, AM-1090), and RU29246. (1991) (8)
Comparison of the lysis centrifugation and radiometric blood culture systems for recovery of yeast (1988) (8)
Variation from standards in Staphylococcus aureus susceptibility testing. (1987) (8)
Potencies of Newer Fluoroquinolones against Viridans Group Streptococci Isolated in 637 Cases of Bloodstream Infection in the SENTRY Antimicrobial Surveillance Program (1997 to 1999): Beyond Canada! (2000) (8)
CHAPTER 4 – The laboratory and clinical mycology (2009) (8)
Multicenter evaluation of the antimicrobial activity for six broad-spectrum beta-lactams in Venezuela using the Etest method. The Venezuelan Antimicrobial Resistance Study Group. (1998) (8)
Russian Klebsiella pneumoniae isolates that express extended-spectrum beta-lactamases. (2000) (8)
Improved urine screening using a combination of leukocyte esterase and the Lumac system. (1985) (8)
Proposed quality control guidelines for National Committee for Clinical Laboratory Standards Susceptibility Tests using the veterinary antimicrobial agent tiamulin. (2001) (8)
In vitro activity of isavuconazole versus opportunistic filamentous fungal pathogens from the SENTRY Antifungal Surveillance Program, 2017-2018. (2020) (7)
Antifungal susceptibilities of opportunistic filamentous fungal pathogens from the Asia and Western Pacific Region: data from the SENTRY Antifungal Surveillance Program (2011–2019) (2021) (7)
Development of Neisseria gonorrhoeae in vitro susceptibility test methods for cefixime including quality control guidelines. (1991) (7)
Activity of a Long-Acting Echinocandin (CD101) and Comparator Antifungal Agents Tested Against Contemporary Worldwide Invasive Fungal Isolates (2016) (7)
Prospective evaluation of the Gen-Probe assay for detection of Legionellae in respiratory specimens (1988) (7)
Multilaboratory Testing of Antifungal Drug Combinations against Candida Species and Aspergillus fumigatus: Utility of 100 Percent Inhibition as the Endpoint (2014) (7)
Comparison of the In Vitro Susceptibility of Ceftolozane-Tazobactam With the Cumulative Susceptibility Rates of Standard Antibiotic Combinations When Tested Against Pseudomonas aeruginosa From ICU Patients With Bloodstream Infections or Pneumonia (2019) (7)
Colonization with coagulase-negative staphylococci in two neonatal units. (1992) (7)
Ceftaroline Activity Tested Against Bacterial Isolates Causing Community-acquired Respiratory Tract Infections and Skin and Skin Structure Infections in Pediatric Patients From United States Hospitals: 2012-2014. (2017) (7)
Development of in vitro susceptibility testing methods for gemifloxacin (formerly LB20304a or SB-265805), an investigational fluoronaphthyridone. (1999) (7)
Interpretive criteria and quality control guidelines for lomefloxacin and meropenem in susceptibility tests of Haemophilus influenzae using Haemophilus test medium. (1992) (7)
Diagnostic Applications of DNA Probes (1991) (6)
Laboratory Diagnosis of Catheter- Related Bacteremia (1995) (6)
Multicenter evaluation of the in vitro activity of six broad-spectrum beta-lactam antimicrobial agents in Puerto Rico. The Puerto Rico Antimicrobial Resistance Study Group. (1998) (6)
Candida albicans isolates from APECED patients show decreased susceptibility to miconazole. (2009) (6)
Emerging Resistance to Azoles and Echinocandins: Clinical Relevance and Laboratory Detection (2010) (6)
Utility of Antifungal Susceptibility Testing and Clinical Correlations (2012) (6)
MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) results from the Americas: resistance implications in the treatment of serious infections. MYSTIC Study Group (Americas). (2000) (6)
Re-evaluation of the Role of Broad-Spectrum Cephalosporins Against Staphylococci by Applying Contemporary In-Vitro Results and Pharmacokinetic- Pharmacodynamic Principles (2007) (6)
Candida species: emerging hospital bloodstream pathogens. (1991) (6)
In vitro assessment of gatifloxacin spectrum and potency tested against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae isolates from the Asia-Western Pacific component of the SENTRY antimicrobial surveillance program (1998-1999). (2002) (6)
Effects of Cilofungin ( LYI 21019 ) on Carbohydrate and Sterol Composition of Candida albicans (6)
Diekema Microdilution Methods , 2010 to 2012 and Laboratory Standards Institute Broth Testing of Candida spp . by Use of Clinical Progress in Antifungal Susceptibility (2012) (6)
Surveillance of omadacycline activity tested against clinical isolates from the United States: Report from the SENTRY Antimicrobial Surveillance Program, 2019: Omadacycline 2019 Surveillance - USA. (2021) (6)
In Vitro Activities of Voriconazole, Fluconazole, and Itraconazole against 566 Clinical Isolates of Cryptococcus neoformans from the United States and Africa (1999) (6)
Oral β-lactams in the treatment of acute otitis media (2007) (5)
In vitro activity of cefepime and other broad-spectrum beta-lactams tested against 129 mec A-negative Staphylococcus spp. isolates: a multicenter sample. (1998) (5)
A Multi-Center Outbreak of Candida tropicalis Bloodstream Infections Associated with Contaminated Hemodialysis Machine Prime Buckets. (2021) (5)
Cephalosporins and Related Drugs (2010) (5)
Presumptive Identification of Candida kefyr on Levine Formulation of Eosin Methylene Blue Agar (2002) (5)
Delafloxacin In Vitro Broth Microdilution and Disk Diffusion Antimicrobial Susceptibility Testing Guidelines: Susceptibility Breakpoint Criteria and Quality Control Ranges for an Expanded-Spectrum Anionic Fluoroquinolone (2018) (5)
Multicenter evaluation of antimicrobial resistance to six broad-spectrum beta-lactams in Colombia using the Etest method. The Colombian Antimicrobial Resistance Study Group. (1997) (5)
Interpretive criteria and quality control guidelines for Neisseria gonorrhoeae susceptibility test standardization for cefotetan (1991) (5)
Polyamine depletion and growth inhibition ofCryptococcus neoformans by α-difluoromethylornithine and cyclohexylamine (1990) (5)
Epidemiology of fungal infections: current perspectives and future directions. Introduction. (1995) (5)
Invasive mycoses: evolving challenges and opportunities in antifungal therapy (multimedia activity). (2011) (5)
Comparison ofBrothMacrodilution, BrothMicrodilution, and E TestAntifungal Susceptibility Tests forFluconazole (1994) (5)
Manual of clinical microbiology: Volumes 1 and 2. (2003) (5)
Isavuconazole nonwildtype Aspergillus fumigatus isolates from a global surveillance study display alterations in multiple genes involved in the ergosterol biosynthesis pathway not previously associated with resistance to other azoles (2021) (5)
In vitro evaluation of contemporary beta-lactam drugs tested against viridans group and beta-haemolytic streptococci. (1997) (5)
In vitro activity of posaconazole and comparators versus opportunistic filamentous fungal pathogens globally collected during 8 years. (2021) (5)
Global view of antimicrobial resistance. Findings of the SENTRY Antimicrobial Surveillance Program, 1997-1999. (2001) (5)
Evaluation of laboratory methods for the classification of oxacillin-resistant and oxacillin-susceptible Staphylococcus aureus. (1988) (5)
Laboratory detection of potential agents of bioterrorism. (2006) (5)
In vitro activity of gatifloxacin tested against anaerobic bacteria by reference agar dilution and Etest methods. (1999) (5)
Diagnosis of disseminated candidiasis in hospitalized patients using the Cand-Tec latex agglutination assay (1992) (5)
Application of DNA probes to antimicrobial susceptibility testing of Legionella pneumophila. (1991) (5)
A case of recurrent episodes of Candida parapsilosis fungemia (2006) (5)
Growth inhibition of pathogenic yeast isolates by α-difluoromethylornithine: An inhibition of ornithine decarboxylase (1987) (5)
Multicenter comparison of MicroScan and BACTEC blood culture systems (1987) (5)
Ceftolozane-Tazobactam Activity Against Clinical Isolates of Pseudomonas aeruginosa from ICU Patients with Pneumonia: United States, 2015-2018. (2021) (4)
Introduction to the 11th Edition of the Manual of Clinical Microbiology (2015) (4)
In vitro comparison of mezlocillin and piperacillin plus tobramycin or gentamicin versus 100 gram-negative nosocomial bloodstream isolates. (1990) (4)
Activity of Delafloxacin When Tested Against Bacterial Surveillance Isolates Collected in the US and Europe During 2014–2016 as Part of a Global Surveillance Program (2017) (4)
Definitions and Epidemiology of Candida Species not Susceptible to Echinocandins (2011) (4)
Phenotypic and genotypic characterizations of Chinese strains of Escherichia coli producing extended-spectrum beta-lactamases. (1999) (4)
Update on the activity of delafloxacin on acute bacterial skin and skin structure infection isolates from European hospitals (2014-2019). (2020) (4)
378. Candida auris Fungemia: Risk Factors and Outcome (2018) (4)
Azole Resistance in Candida glabrata Clinical Isolates from Global Surveillance is Associated with Efflux Overexpression. (2022) (4)
Comparative evaluation of an automated ribotyping instrument versus pulsed-field gel electrophoresis for epidemiological investigations of clinical isolates (1997) (4)
Erratum for Pfaller et al., “In Vitro Activity of Delafloxacin against Contemporary Bacterial Pathogens from the United States and Europe, 2014” (2018) (4)
In Vitro Activity of Anidulafungin and Other Agents against Esophageal Candidiasis-Associated Isolates from a Phase 3 Clinical Trial (2010) (3)
Advances in Antifungal Susceptibility Testing of Candida, 2010–2012 (2012) (3)
Posaconazole MIC distributions for Aspergillus fumigatus SC by four methods: Impact of Cyp51A mutations on estimation of epidemiological cutoff values (ECVs/ECOFFs) (2018) (3)
Antimicrobial Activity of Ceftolozane–Tazobactam Tested against Contemporary (2012–2016) Enterobacteriaceae and Pseudomonas aeruginosa Isolates by US Census Division (2017) (3)
Comparative antimicrobial spectrum and activity of BMS284756 (T-3811; a desfluoroquinolone) tested against an international collection of staphylococci and enterococci, including in vitro test development and intermethod comparisons. (2002) (3)
Comparative activity of posaconazole and systemic azole agents against clinical isolates of filamentous fungi from a global surveillance programme (2021) (3)
Significance of Molecular Identification and Antifungal Susceptibility of Clinically Significant Yeasts and Moulds in a Global Antifungal Surveillance Programme (2012) (3)
A Multi-Site Evaluation of Two New Echinocandins, Anidulafungin (AND), and Micafungin (MF) on a Colorimetric MIC Susceptibility Test Plate Compared with the CLSI M27 Reference Broth Micro Dilution (BMD) Plate for Antifungal Susceptibility Testing (2007) (3)
Oral beta-lactams in the treatment of acute bacterial rhinosinusitis. (2007) (3)
Leptospirosis and limb gangrene. Case report. (1979) (3)
Nosocomial gram-negative bloodstream isolates: a comparison of in vitro antibiotic potency. (1989) (3)
Laboratory Diagnosis of Infections Due to Legionella Species: Practical Application of DNA Probes in the Clinical Microbiology Laboratory (1988) (3)
Oral h-lactams in the treatment of acute otitis media (2007) (2)
Analysis of Oritavancin Activity against Gram-Positive Clinical Isolates Responsible for Bacterial Endocarditis in United States and European Hospitals (2008–2016) (2017) (2)
Antimicrobial activity of oritavancin and comparator agents when tested against Gram-positive bacterial isolates causing infections in cancer patients (2014–16) (2018) (2)
Coagulase-negative staphylococci: Why and when to do what (1989) (2)
In vitro inhibitory and bactericidal activity of cefpiramide and seven antipseudomonal agents against Pseudomonas aeruginosa. (1986) (2)
Accuracy of broth microdilution and E test methods for detecting chloramphenicol acetyl transferase mediated resistance in Streptococcus pneumoniae: Geographic variations in the prevalence of resistance in The SENTRY Antimicrobial Surveillance Program (1999). (2001) (2)
Oral beta-lactams in the treatment of acute otitis media. (2007) (2)
Comparison oftheAutoSCAN-W/A RapidBacterial Identification SystemandtheVitek AutoMicrobic Systemfor Identification ofGram-Negative Bacilli (1991) (2)
Restriction endonuclease analysis ofStaphylococcus aureus plasmid DNA from three continents (2005) (2)
Automated instrument approaches to clinical microbiology. (1985) (2)
2400. Activity of a Long-Acting Echinocandin, Rezafungin, Tested Against Invasive Fungal Isolates Collected Worldwide (2018) (2)
Antimicrobial interactions of trovafloxacin and extended-spectrum cephalosporins or azithromycin tested against clinical isolates of Pseudomonas aeruginosa and Stenotrophomonas maltophilia. (1998) (2)
Reduced Intravascular Infection by Antibiotic Bonding-Reply (1991) (2)
Elderly versus nonelderly patients with invasive fungal infections: species distribution and antifungal resistance, SENTRY antifungal surveillance program 2017-2019. (2021) (2)
Antimicrobial activity of RU29246 (HR916 metabolite) compared with four other oral beta-lactams tested against more than 5000 clinical isolates (1991) (2)
Diagnostic applications of DNA probes. (1991) (2)
Evaluation of Rezafungin Provisional CLSI Clinical Breakpoints and Epidemiological Cutoff Values Tested against a Worldwide Collection of Contemporaneous Invasive Fungal Isolates (2019 to 2020) (2022) (2)
Fixed-Ratio Combination Testing of an Echinocandin, Anidulafungin, and an Azole, Voriconazole, against 1,467 Candida Species Isolates (2010) (2)
Gatifloxacin (AM-1155, CG 5501) susceptibility testing interpretive criteria and quality control guidelines for dilution and disk (5-microgram) diffusion methods. The Quality Control Study Group. (1999) (2)
Strategies to Affect Laboratory Test Utilization in a Budget Constrained Environment (2002) (1)
Antifungal drugs work together to treat germs causing fungal infections (2021) (1)
Impact of COVID-19 on the antifungal susceptibility profiles of isolates collected in a global surveillance program that monitors invasive fungal infections (2022) (1)
Inhibitors of HIV Protease (2010) (1)
Activity of ceftolozane-tazobactam and comparators when tested against bacterial surveillance isolates collected from patients at risk of infections caused by resistant gram-negative pathogens. (2020) (1)
Ceftobiprole activity against Gram-positive and Gram-negative pathogens causing bone and joint infections in the United States from 2016 to 2020. (2022) (1)
Antimicrobial Activity of Dalbavancin Tested against Staphylococcus aureus with Decreased Susceptibility to Glycopeptides, Daptomycin, and/or Linezolid from United States (US) Medical Centers (2017) (1)
Direct in vitro comparison of the prodrug isavuconazonium sulfate with the isavuconazole active compound against Aspergillus spp. and 2 rare moulds. (2018) (1)
Activity of Ceftolozane-Tazobactam Against Gram-Negative Isolates from Australia and New Zealand as part of the PACTS Surveillance 2016-2018. (2022) (1)
2115. Activity of a Long-Acting Echinocandin Rezafungin and Comparator Antifungal Agents Tested against Contemporary Invasive Fungal Isolates: SENTRY 2018 (2019) (1)
1454Antifungal Susceptibility Patterns of a Global Collection of Fungal Isolates and Polysorbate-80 Effect on the Susceptibility of the Antifungal Classes (2014) (1)
RESULTS OF A DOUBLE-BLIND, DOUBLE SHAM STUDY OF ANTACIDS VERSUS SUCRALFATE STRESS ULCER PROPHYLAXIS (1993) (1)
Multicenter Collaborative Study of the Interaction of Antifungal Combinations against Candida Spp. by Loewe Additivity and Bliss Independence-Based Response Surface Analysis (2022) (1)
In Vitro Susceptibility of Invasive Isolates of Candida spp. to Anidulafungin, Caspofungin, and Micafungin: Six Years of Global Surveillance (2008) (1)
Glycopeptides and Lipopeptides (2010) (1)
Agents Active Against American Trypanosomiasis (2010) (1)
1260. Activity of Manogepix (APX001A) against 2,669 Fungal Isolates from the SENTRY Surveillance Program (2018-2019) Stratified by Infection Type (2020) (1)
1253. In Vitro Activity of Omadacycline against 7000 Bacterial Pathogens from the United States Stratified by Infection Type (2019) (2020) (1)
Dalbavancin I n Vitro Activity Obtained Against Gram-positive Clinical Isolates Causing Osteomyelitis in USA Hospitals (2011 - 2015) (2016) (1)
2043. In Vitro Activity of Manogepix Against 2,810 Fungal Isolates from the SENTRY Surveillance Program (2020-2021) Stratified by Infection Type (2022) (1)
In Vitro Activity of Omadacycline and Comparator Compounds Against Gram-positive Isolates Collected in the USA During 2016 as Part of a Global Surveillance Program (2017) (1)
Activities of Manogepix and Comparators against 1,435 Recent Fungal Isolates Collected during an International Surveillance Program (2020) (2022) (1)
Initial report of a longitudinal, international antimicrobial surveillance study Alarming resistance rates in monitored sites in the USA, Canada, South America, and Europe (1997) (1)
In-vitro activity of paldimycin against methicillin-resistant and susceptible isolates of Staphylococcus aureus and S. epidermidis. (1987) (1)
Activity of Anidulafungin and Other Antifungal Agents: Results from an International Surveillance Program (2006-2007) (2008) (0)
Agents Active Against Ectoparasites (2010) (0)
REDUCED INTRAVASCULAR INFECTION BY ANTIBIOTIC BONDING. AUTHORS' REPLY (1991) (0)
Geographic and Temporal Trends in Isolation and Antifungal Susceptibility of Candida parapsilosis : a Global Assessment from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005 (cid:1) (2008) (0)
Beta-Lactamase Inhibitors and Combinations (2010) (0)
2044. In Vitro Activity of Omadacycline Against 14,000 Bacterial Isolates from the United States by Infection Type (2020-2021) (2022) (0)
1591. Updated Fluoroquinolone MIC Breakpoints: Impact on Susceptibility Rates in the United States (2019) (0)
Evaluation of In Vitro Activity of Ceftaroline Tested against Streptococcus pneumoniae Isolates from United States Hospitals: Results from 7 Years of the AWARE Surveillance Program (2010–2016) (2017) (0)
P1966 FKS mutation in echinocandin-resistant C. glabrata (2007) (0)
Comparative in vitro activity of the new quinolone sparfloxacin (CI-978, AT-4140) against nosocomial gram-negative bloodstream isolates (1990) (0)
Antifungal Activity of Isavuconazole and Comparator Agents against Contemporaneous Mucorales Isolates from USA, Europe, and Asia-Pacific (2023) (0)
using genomic DNA typing methods. in a surgical intensive care unit cluster by Investigation of Candida albicans transmission (2013) (0)
Agents Active Against the Human Immunodeficiency Virus (2010) (0)
Aerosolization of microbes from patients on air-flotation beds (1989) (0)
Agents Active Against Helminths (2010) (0)
Correction: Antifungal susceptibilities of opportunistic filamentous fungal pathogens from the Asia and Western Pacific Region: data from the SENTRY Antifungal Surveillance Program (2011–2019) (2021) (0)
Inhibitors of Reserve Transcriptase (2010) (0)
1076. Activity of Rezafungin and Comparator Antifungal Agents Tested Against a Worldwide Collection of Contemporaneous Invasive Fungal Isolates (2019-2020) (2021) (0)
HeparinInterfereswiththe RadioenzymaticandHomogeneousEnzyme Immunoassaysfor Aminoglycosides (2004) (0)
Use of Fluconazole as a Surrogate Marker To Predict Susceptibility and Resistance to Voriconazole among 13,338 Clinical Isolates of Candida spp. Tested by Clinical and Laboratory Standards Methods (2006) (0)
Coagulase-Negative Staphylococcal Bacteremia (2020) (0)
Diffusion Testing Voriconazole by Standardized Disk Other Yeast Species to Fluconazole and and Candida Analysis of Susceptibilities of Antifungal Surveillance Study: a 6.5-Year Results from the ARTEMIS DISK Global (2014) (0)
Other Anti-HIV Agents (2010) (0)
Antimicrobial Activity of Gatifloxacin Against Campylobacter jejuni and Anaerobic Bacteria (1999) (0)
Activity of Dalbavancin Tested Against Gram-positive Clinical Isolates Causing Skin and Skin Structure Infections in Pediatric Patients from USA Hospitals (2014 - 2015). (2016) (0)
Gatifloxacin Susceptibility Testing Interpretive Criteria and Quality Control Guidelines for Dilution and Disk Diffusion Methods (1999) (0)
Agents Active Against Intestinal and Intra-Abdominal Protozoa (2010) (0)
Topical Agents - Thiocarbamates, Hydroxypridones and Morpholine (2010) (0)
Clinical Isolates ofCandida spp. and Four Other Antifungal Agents against 394 In Vitro Activities of Voriconazole (UK-109,496) (2013) (0)
PCR and Invasive Candidiasis: A Meta-Analysis (2011) (0)
Screening of a large , global Aspergillus fumigatus species complex collection using a 1 species specific microsphere based Luminex assay 2 3 4 (2009) (0)
Interpretative Susceptibility Breakpoints for Antifungal Agents (2006) (0)
Staphylococcus aureus conjunctivitis and sepsis in a neutropenic patient. (1989) (0)
Anti-Parasitic Drugs (2010) (0)
Other Antifungal Agents and New Agents in Development (2010) (0)
Antimicrobial Activity of Ceftolozane–Tazobactam Tested against Contemporary (2012–2016) Enterobacteriaceae and Pseudomonas aeruginosa from ICU vs. non-ICU Isolates Collected in US Medical Centers (2017) (0)
Agents Active Against Hepatitis Viruses (2010) (0)
This question was referred to Michael A. Pfaller, MD (1989) (0)
665. In vitro Activity of Omadacycline Against Recent (2018) Bacterial Pathogens from the United States and Europe Obtained from Skin and Skin Structure, Respiratory, and Urinary Tract Infections (2019) (0)
eight-center collaborative study. neoformans with and without agitation: an of Candida albicans and Cryptococcus Microdilution antifungal susceptibility testing (2013) (0)
ANTIBIOTIC BONDING SIGNIFICANTLY REDUCES CUMULATIVE RISK OF INTRAVASCULAR CATHETER INFECTION (1990) (0)
[Methicillin-resistant Staphylococcus aureus]. (1992) (0)
1240. Ceftobiprole Activity against Drug-Resistant Staphylococcus aureus Clinical Isolates Collected in the United States from 2016 through 2020 (2021) (0)
Activity of Isavuconazole and Comparator Mould-Active Triazoles Tested against Contemporary Invasive Mould Isolates (2016) (0)
Analysis of Candida Auris Fungemia at a Single Facility in Kenya (2019) (0)
In Vitro Antimicrobial Activity of Gatifloxacin Against N. gonorrhoeae and H. influenzae (1999) (0)
Anti-Folate Agents and Other Synthetic Antibacterials (2010) (0)
Anti-Fungal Drugs (2010) (0)
Agents Active Against Leishmania and Other Pathogens (2010) (0)
Agents Active Against Respiratory Viruses (2010) (0)
In vitro activity of a novel aminomethylcycline antibacterial (KBP-7072), a third-generation tetracycline, against clinical isolates with molecularly characterized tetracycline resistance mechanisms (2021) (0)
1081. Antimicrobial Activity of Dalbavancin Tested Against Gram-Positive Organisms Isolated From Patients With Infective Endocarditis in United States and European Medical Centers (2018) (0)
868. In Vitro Activity of Isavuconazole and Other Mould-Active Triazoles Against Aspergillus fumigatus With and Without cyp51 Alterations (2022) (0)
P1273 Activity of posaconazole against clinical isolates of Candida albicans with decreased sensitivity tofiuconazole from autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy patients (2007) (0)
Clinical Breakpoints for Fluconazole Yeast Susceptibility Test Using New CLSI Multicenter Evaluation of the New Vitek 2 (2014) (0)
Posaconazole , and Voriconazole Values for Fluconazole , Itraconazole , Distributions and Epidemiological Cutoff Study of Wild-Type Susceptibility Endpoint gattii Species Complex : an International Cryptococcus neoformans-Cryptococcus (2012) (0)
Reading Fluconazole Susceptibility after 24 Hours: Validation against the Clinical and Laboratory Standards Institute (CLSI) Reference Methods (2008) (0)
Interpretive Criteria andQuality Control Guidelines forNeisseria gonorrhoeae Susceptibility TestStandardization forCefotetan (1991) (0)
Echinocandins, Allylamines and Benzylamine Derivatives (2010) (0)
Isavuconazole and Nine Comparator Antifungal Susceptibility Profiles for Common and Uncommon Candida Species Collected in 2012: Application of New CLSI Clinical Breakpoints and Epidemiological Cutoff Values (2014) (0)
Plain language summary: Does a person's age affect how common fungal infections are and how well drugs can kill the infections? (2022) (0)
Ceftolozane/Tazobactam Activity Against Drug-Resistant Pseudomonas aeruginosa and Enterobacterales Causing Healthcare-Associated Infections in Eight Asian Countries: Report from an Antimicrobial Surveillance Program (2016–2018) (2022) (0)
Antimicrobial Activity of Gatifloxacin Tested Against 1676 Gram-Positive Cocci Resistant to Ciprofloxacin (1999) (0)
Correction: Antifungal susceptibilities of opportunistic filamentous fungal pathogens from the Asia and Western Pacific Region: data from the SENTRY Antifungal Surveillance Program (2011–2019) (2021) (0)
Head-to-head comparison of micafungin versus caspofungin in the treatment of invasive candidiasis (2009) (0)
Antimicrobial Spectrum of Gatifloxacin in the SENTRY Program (1999) (0)
Agents Active Against Herpesviruses (2010) (0)
INFECTION OF INTRAVASCULAR CANNULAE: INFLUENCE OF ANTIBIOTIC BONDING (1988) (0)
Activity of Ceftolozane-Tazobactam and Comparators When Tested against Bacterial Surveillance Isolates Collected from Pediatric Patients in the US during 2012–2016 as Part of a Global Surveillance Program (2017) (0)
Tetracyclines and Related Drugs (2010) (0)
A plain language summary of the EXPLORER-HCM study: mavacamten for obstructive hypertrophic cardiomyopathy. (2021) (0)
FOCUS Antifungal Susceptibility Testing: Practical Aspects and Current Challenges (2001) (0)
1004. Frequency of Occurrence and Antimicrobial Susceptibility of Bacteria Isolated From Patients Hospitalized With Bloodstream Infections in United States Medical Centers (2015–2017) (2018) (0)
Hatschi-Gesundheit Sneezing Staphylococcus aureus into the air during a common cold (2002) (0)
Evaluation of the Post‐Antifungal Effect of Rezafungin and Micafungin against Candida albicans, Candida parapsilosis and Candida glabrata (2022) (0)
Anti-Tuberculous Drugs (2010) (0)
1595. Ceftobiprole Activity against Gram-Positive Pathogens Causing Bone and Joint Infections in the United States from 2016 through 2019 (2020) (0)
Failure to isolate methicillin-resistantStaphylococcus aureus from stethoscopes in two hospitals with endemic strains (2005) (0)
Role of the microbiology laboratory in monitoring and identifying resistance: use of molecular biology. (1996) (0)
Anti-Viral Drugs (2010) (0)
Restriction endonuclease analysis (REA) and pulsed-field gel electrophoresis (PFGE) for differentiating strains of enterococci: An assessment using clinical epidemiologie data (1997) (0)
Diekema fumigatus Aspergillus and Candida albicans beyondPathogens : Concern for Resistance Rare and Emerging Opportunistic Fungal (2004) (0)
347. Azole Activity against Filamentous Fungi Causing Invasive Infections in Patients from ICU and Non-ICU Units (2017-2021) (2022) (0)
Antimicrobial Activity of Dalbavancin and Comparator Agents Tested against Gram-Positive Clinical Isolates Causing Bone and Joint Infections in United States (US) Medical Centers (2011–2016) (2017) (0)
Ronald N. Jones, MD, editor-in-chief, diagnostic microbiology and infectious disease, 1989-2013. (2013) (0)
Tedizolid in vitro activity against Gram-positive clinical isolates causing bone and joint infections in hospitals in the USA, Europe, Latin America, and the Asia-Pacific region (2015-2019). (2022) (0)
1258. Activity of a Series of Investigational Compounds Tested Against Invasive Fungal Isolates (2020) (0)
Quinolones and Fluoroquinolones (2010) (0)
Identification of Uncommon Clinically Important Yeasts and Moulds by the Bruker Biotyper Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry (MALDI-TOF MS) System in a Global Antifungal Surveillance Program (2015) (0)
AN EPIDEMIOLOGIC UPDATE ON INVASIVE FUNGAL INFECTIONS * — (2004) (0)
Macrolides and Ketolides (2010) (0)
Effect ofSerumon theInVitro Activities of 11Broad-Spectrum Antibiotics (1990) (0)
1590. Updated Aminoglycoside (AG) MIC Breakpoints (BP) to Minimize Adverse Events and Improve Outcome: Impact on Susceptibility (S) Rates (2019) (0)
Penicillins and Related Drugs (2010) (0)
P1274 Decreased sensitivity of Candida albicans for azole antifungals - a complication of long-term prophylaxis in APECED patients (2007) (0)
and Interpretive Criteria of Candida by Using CLSI Methods and Caspofungin among 4 , 290 Clinical Isolates To Predict Susceptibility and Resistance to Use of Anidulafungin as a Surrogate Marker (2014) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Michael A. Pfaller?

Michael A. Pfaller is affiliated with the following schools:

Washington State University
MD Anderson Cancer Center
Wake Forest University
Virginia Commonwealth University
Stanford University
University of Iowa